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HIV  human immunodeficiency virus 
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LS180  human colon carcinoma cell line 
MDR  multi-drug resistance 
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NCBI  National Center for Biotechnology Information 
NFκB  nuclear factor κB 
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P(app)  apparent permeability coefficient 
PCR  polymerase chain reaction 
PGE2  prostaglandin E2 
P-gp  P-glycoprotein 
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pSUPER vector system 
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RNA  ribonucleic acid 
RNAi  RNA interference 
RT-PCR reverse transcription polymerase chain reaction 
RXR  retinoic X receptor (9-cis retinoic acid receptor) 
SEM  standard error of the mean 
shRNA small haipin ribonucleic acid 
siRNA  single strand ribonucleic acid 
SNP  single nucleotide polymorphism 
TM  transmembrane 
TNF-α  tumor necrosis factor α 
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Summary 
The intestine has an important role in facilitating and limiting absorption of drugs. Since the 
intestine forms a barrier to the external, epithelial cells have several properties to protect the body 
from microorganisms and toxins, and to control uptake of xenobiotics. This barrier system 
consists of tight-junction proteins which minimise paracellular uptake and on the other hand of 
membrane transport proteins and metabolic enzymes, which regulate transcellular uptake. 
Membrane transporters are very important in regulating drug absorption, distribution and 
extrusion. They are expressed in many tissues and regulate transport of endogenous and 
exogenous substances. ATP-binding cassette transporters (ABC-transporters) form a huge class of 
membrane transporters which are involved in drug transport. They exhibit large substrate 
specificity and effectively regulate drug absorption in the intestine. Induction or inhibition of 
these transporters may influence drug bioavailability of orally ingested drugs. 
The aim of the thesis was to investigate the impact of ABC-transporters on intestinal drug 
absorption. The second purpose was to gain insight into transcriptional regulation of these 
transporters. 
Two highly expressed ABC-transporters in the intestine, ABCB1 (P-gp, MDR1) and ABCG2 
(BCRP), which have a broad and partly overlapping substrate specificity were of special interest in 
this thesis. The impact of P-gp and BCRP on transport of substrates, which are transported by 
both transporters, was investigated in the intestinal cell line Caco-2. A stable cellular in vitro 
system with single and concomitant knock-down of P-gp and BCRP was established using the 
method of mRNA silencing. Stable Caco-2 clones with selective, single knock-down of P-gp 
(siMDR1) and BCRP (siBCRP) and with concomitant knock-down of both transporters (co-
silencing) were generated and characterised on the level of mRNA and protein expression. 
Additional functional characterisation was performed by transport and efflux studies using 
selective substrates of each transporter (chapter 3.1). 
Compounds which are substrates of P-gp and BCRP were examined in this Caco-2 cell system by 
transport studies. The tyrosin-kinase inhibitor imatinib and the anti-retroviral drug abacavir are 
described to be substrates of both, P-gp and BCRP. Bidirectional transport of imatinib was 
observed in Caco-2 wild-type and BCRP-silencing clones, but no bidirectional transport was seen 
Summary 
11 
in P-gp- and co-silencing clones. Since bidirectional transport means active transport processes, 
these results might suggest that P-gp possibly compensates transport in clones where only BCRP 
is silenced but BCRP does not when P-gp is silenced. We therefore concluded that P-gp might 
play a more important role in intestinal imatinib transport, but disturbing factors such as possible 
silencing off-target effects of our cell system have to be ruled out in further studies. Transport of 
abacavir showed a similar tendency as imatinib, but effects were only small and further 
evaluations have to be performed (chapter 3.2). 
Regulation of P-gp in the intestinal cell lines Caco-2 and LS180 was investigated. Since 
budesonide is a frequently used glucocorticoid in inflammatory bowel disease (IBD), we 
investigated how budesonide influences P-gp expression in these intestinal cell lines. We observed 
differential effects in the two intestinal cell lines; budesonide showed an induction of P-gp in 
LS180 cells and a downregulation in Caco-2 cells. Expression levels of nuclear receptors revealed 
high expression of pregnane X receptor (PXR) only in LS180 cells and exclusive expression of 
glucocorticoid receptor (GR) in Caco-2 cells. Mifepristone, an anti-glucocorticoid, could not 
reverse the downregulation of P-gp by budesonide in Caco-2 cells. In PXR-transfected Caco-2 
cells the budesonide-mediated downregulation of P-gp was abolished. Furthermore the expression 
of cytochrome P450 3A4 (CYP3A4), another target gene, was induced in PXR-transfected Caco-
2 cells after budesonide treatment. Therefore, the induction of P-gp by budesonide in LS180 cells 
probably is mediated via PXR. However, the mechanism of the downregulation in Caco-2 cells 
still remains unclear, but GR does not seem to be involved (chapter 4.1). 
In a collaboration, interactions of budesonide with the PXR-target gene CYP3A4 was investigated 
in comparison to other glucocorticoids. Induction studies in LS180 cell line and in a hPXR-
transactivation assay showed, that budesonide significantly induced intestinal CYP3A4 while 
other glucocorticoids did not. In vivo data in mice showed that budesonide and dexamethasone 
induced intestinal CYP3a11 while only dexamethasone induced liver CYP3a11. These data 
indicated that budesonide has the potential to induce intestinal PXR target genes but only to a 
small extent and therefore, the risk for interactions seems to be low (chapter 4.2). 
Caco-2 cells represent a good in vitro model for the small intestine but do not express functional 
active PXR. Therefore we aimed to establish a Caco-2 cell model with stable transfected PXR. We 
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successfully transfected Caco-2 cells with PXR. Induction of PXR target genes P-gp and CYP3A4 
was achieved after induction with the PXR-ligand rifampicin. However, the effects were not as 
pronounced as in LS180 cells and therefore additional investigations are indicated (chapter 4.3). 
In further studies, effects of curcuma longa L. extracts and single curcuminoids on transcriptional 
regulation of ABC-transporters, CYP enzymes and pro-inflammatory proteins were investigated. 
Curcumin is described as anti-inflammatory agent and is discussed as possible therapy for 
intestinal inflammation. Our data in tumor-necrosis-factor-α (TNF-α) induced LS180 cells 
indicate that curcuminoids reduce mRNA expression of different proteins involved in 
inflammation such as iNOS, TNF-α and COX-2. Additionally, the curcuma extract was shown 
to directly inhibit cyclooxygenase-2 (COX-2) activity (chapter 5.2). Curcuma extracts and 
curcuminoids showed no relevant effects on P-gp and CYP mRNA expression in LS180 cells 
indicating no interaction potential of curcuminoids and curcuma extracts on the level of 
transcriptional regulation (chapter 5.1). Effects of curcuma extracts and curcuminoids on 
inflammatory proteins and ABC-transporters or CYP expression have to be confirmed in vivo.  
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Aim of the Thesis 
The aim of this thesis was to investigate the impact of ABC-transporters on drug absorption in 
the intestine. Of special interests therein were two important intestinal efflux transporters, P-
glycoprotein and breast cancer resistance protein.  
Furthermore, transcriptional regulation of intestinal P-gp and CYPs by topical effective anti-
inflammatory drugs in the intestine was of interest. Of special concern was transcriptional 
regulation via the nuclear receptor PXR. 
 
In order to fulfill the above mentioned aims, the following topics were investigated: 
• Establishment of a stable Caco-2 cell culture model with selective knock-downs of P-gp 
and BCRP and additionally a concomitant knock-down of both transporters. 
• Testing of drugs described to be substrates of both, P-gp and BCRP, and determining the 
impact of each transporter on transport of these substrates. 
• Investigation of the influence of budesonide on transcriptional regulation of P-gp in 
Caco-2 and LS180 intestinal cell lines. 
• Determination of the role of PXR in transcriptional regulation of P-gp and CYP3A4 by 
budesonide. 
• Establishment of a PXR-inducible Caco-2 system by stable transfection of PXR. 
• Investigation of curcuma extracts and curcuminoids on the regulation of ABC-
transporters and CYPs. 
• Investigation of a curcuma extract and curcuminoids on anti-inflammatory effects in an 
intestinal cell line. 
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1 Introduction 
 
1.1 Drug Absorption in the Intestine 
The intestine forms a barrier between the organism and the external environment. Major tasks of 
intestinal tissue comprise absorption of nutrients and protection against toxins and 
microorganisms. The intestine is highly colonised by bacteria; therefore protection against these 
bacteria and bacteria toxins is an important challenge of the intestinal epithelium. Intestinal 
epithelial cells form tight-junctions, which mainly consist of occludin and claudin. These proteins 
prevent paracellular uptake of e.g. toxins. Transcellular uptake is regulated by specific membrane 
pumps and channels (Baumgart and Dignass, 2002). 
Tissue of the small intestine forms finger-like projections called villi with additional microvilli 
resulting in a huge surface extension. Therefore, most ingested nutrients and drugs are absorbed 
in the small intestine. In general passive diffusion along a concentration gradient is a common 
way for transcellular drug absorption in the intestine. However, several factors hinder drug 
absorption and can lead to poor bioavailability. Chemical and physicochemical properties of the 
drug such as the molecular weight, the amount of proton bond acceptors and donors or LogP-
values (octanol-water partition coefficient) are important factors which determine drug 
absorption (Lipinski et al., 2001). Solubility in the intestinal fluid is a further requirement for 
drug absorption. Systemic bioavailability of drugs is also influenced by an additional set of 
different factors. Instability in acidic pH in the stomach or metabolism by the intestinal 
microflora or by hydrolytic and conjugative enzymes are possible limiting factors for drug 
absorption. In addition to the inactivation by conjugation (phase II metabolism), phase I 
intestinal metabolism is important for reducing bioavailability of oral drugs (Figure 1)(Benet et 
al., 1996). High expression level of the cytochrome P450 (CYP) enzyme family in the mature 
villus tip enterocytes was observed. Among phase I metabolising enzymes, CYP3A4 appears to be 
the most abundant CYP in human enterocytes and liver. (Shimada et al., 1994), (Watkins et al., 
1987), (Kolars et al., 1992). Additionally, CYP3A4 is the most important CYP enzyme in drug 
metabolism since it is responsible for the metabolism of about 50% of available drugs (Benet et 
al., 1996). The fact that CYP3A4 is highly expressed at the villus tip enterocytes where it has 
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contact to the ingested drugs, suggests that intestinal metabolism exhibits an important impact on 
drug absorption. 
In addition to intestinal metabolism, also transport proteins exhibit a significant influence on oral 
drug bioavailability. Carrier mediated uptake enables absorption of hydrophilic drugs. Bile-acid-, 
amino-acid- or oligopeptide-transporters belong to those transporters that facilitate absorption of 
e.g. L-dopa or cephalosporins (Hu and Borchardt, 1990), (Inui et al., 1992). In contrast to these 
uptake transporters, active efflux transporters are able to reduce drug bioavailability. ATP-binding 
cassette transporters represent a huge superfamily of active efflux transporters. Transporters of this 
superfamily were investigated in this thesis and are therefore described in detail (see chapter 1.2). 
 
 
Figure 1 Schematic diagram for mechanisms involved in low bioavailability of cyclosporine A. 14% is not absorbed, 
exported by P-gp or degraded in the lumen. 51% is metabolised in the enterocytes and 8% in hepatocytes. These 
data point out the importance of enterocytes in limiting drug bioavailability (Benet et al., 1996). 
Introduction 
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1.2 ABC-Transporter 
ATP-binding cassette transporters (ABC-transporters) represent a large superfamily of ATP-
driven active efflux transporters. Seven subfamilies are described (ABCA-ABCG), therein 
members of ABCB, ABCC and ABCG subfamilies are involved in drug-transport. The structure 
of these transporters shows extensive sequence homology among the different subfamilies. ABC-
transporters consist in general out of 12 transmembrane (TM) domains with two intracellular 
nucleotide binding sites. Half-transporters with only 6 TM domains and one nucleotide binding 
site are described in the ABCG subfamily. Some transporters of the ABCC subfamily which 
additionally comprise 5 TM domains at the N-terminus make an exception to this general 
structure. 
ABC-transporters are in general located in the cell membrane, where they function as efflux 
pumps. Active extrusion of drugs requires ATP and can proceed against a concentration gradient. 
ABC-transporters were first discovered in tumour cells mediating as multi-drug-resistance 
protein. The first characterised member was P-glycoprotein (P-gp, MDR1, ABCB1) in Chinese 
hamster ovary cells (CHO) (Juliano and Ling, 1976). Identification of multi-drug resistance 
associated transporters (MRPs, ABCC) and breast cancer resistance protein (BCRP, ABCG2) 
followed afterwards. High expression of the mentioned transporters in cancer cells led to therapy 
resistance due to active export of anticancer drugs. Beside the expression in tumour cells, ABC-
transporters are also expressed in healthy tissues. Predominantly, ABC-transporters are expressed 
in tissues which occupy a barrier or excretory function such as blood brain barrier (BBB), kidney, 
liver or intestine. Apical expression in the enterocytes suggests active extrusion into the gut 
lumen, while expression on the basolateral side of enterocytes suggests transport to the blood 
circulation (Figure 2) (Chan et al., 2004). Expression levels of ABC-transporters in the intestine 
were systematically analysed in biopsies from different segments of the gastrointestinal tract. All 
transporters showed alterations in their expression levels from the duodenum to the sigmoid 
colon. Most pronounced changes were observed for MRP2, with high levels in the small intestine 
and very low expression levels in the colon. MDR1 showed highest expression levels in the 
terminal ileum, while BCRP expression was highest in the duodenum and decreased to the 
rectum (Gutmann et al., 2005), (Zimmermann et al., 2005). 
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Figure 2 Expression of ABC-transporters in the small intestine. Expression is mainly in the villus tip enterocytes and 
varies from proximal to distal. Apical expression leads to increased efflux transport and reduced absorption while 
basolateral expression leads to increased absorption (Chan et al., 2004). 
 
The ABC-transporters P-gp (ABCB1, MDR1) and BCRP (ABCG2) were of special interest in 
this thesis, since they play a major role in intestinal export function and have broad and partly 
overlapping substrate specificity. 
 
 
1.2.1 ABCB1 (MDR1, P-gp) 
P-glycoprotein is the first discovered ABC-transporter and therefore probably also the best 
characterised. P-gp was first described in drug resistant CHO cells as membrane glycoprotein 
with a molecular weight of 170 kD. It consists out of 12 TM domains and two nucleotide 
binding domains. It is arranged in cell membranes with the TM domains building an open ring 
of two halves (Figure 3). This arrangement suggests the mechanism of action. There are two 
models for drug-transport. The ‘vacuum cleaner’ model proposes that drugs interact with P-gp 
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within the hydrophobic part of the membrane bilayer, enter the transporter between the two 
halves and are transported to the extracellular space. In the ‘flippase’ model, it is suggested that P-
gp can flip drugs from the inner to the outer leaflet of the bilayer or to the extracellular space 
(Hennessy and Spiers, 2007).  
 
Figure 3 Arrangement of TM domains of P-gp and proposed entrance site for drugs between TM domains 5 and 8 
or TM domains 2 and 11 (Hennessy and Spiers, 2007). 
 
The expression of P-gp is found at high levels in tumour cells indicating its important role in 
multi-drug resistance in anticancer therapy. Besides tumour cells, P-gp is constitutively expressed 
in a wide variety of different normal tissues. The small intestine, colon, liver, kidney, placenta, 
blood-brain-barrier and adrenal gland express P-gp (Cordon-Cardo et al., 1990). P-gp is 
expressed mainly at the apical side where it has its barrier or excretory function. In intestinal 
tissue it is apically expressed in enterocytes of the villus tip and transports its substrates back to 
the intestinal lumen (Figure 2). This location and function indicates the important role of P-gp 
in extruding xenobiotics and toxins to protect the body. A huge number of drugs are substrates of 
P-gp. The chemical structure and pharmacological action of P-gp substrates differs considerably. 
Thus, P-gp recognises substrates from a broad range, but a tendency towards lipophilic cationic 
compounds was described (Zamora et al., 1988). Many important drugs of completely different 
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pharmacological classes such as antibiotics, anticancer agents, cardiac drugs, 
immunosuppressants, antihistamines and steroids are transported by P-gp. Drug-drug 
interactions possibly occur when two substrates of P-gp are applied concomitantly. While one 
drug modifies P-gp function, absorption or clearance of the other drug might change. Such 
interactions are of special importance when one of these drugs has a small therapeutic range. 
Relevant increases in plasma concentrations of e.g. digoxin were described when P-gp function 
was inhibited. (Hager et al., 1979). 
On the other hand, induction of P-gp expression could lead to increased drug clearance or 
reduced absorption leading to insufficient therapy outcome. A broad set of drugs were described 
as inducers of P-gp. Pregnane-X-receptor (PXR) was described to mediate P-gp induction and is 
activated by a variety of xenobiotics (see chapter 1.3.2). Regulation of P-gp expression is very 
complex and far from being fully understood. Analysis on the promoter revealed a set of elements 
where in addition to PXR different factors could bind and regulate gene expression (Labialle et 
al., 2002). 
In addition to drug-drug interactions, single nucleotide polymorphisms (SNPs) are stated to 
influence P-gp function and inducibility. Several SNPs were identified on the MDR1 gene, 
including the wobble mutation at C3435T which was described to be associated with decreased 
P-gp expression, inducibility and function (Hoffmeyer et al., 2000). 
 
1.2.2 ABCG2 (BCRP) 
Breast cancer resistance protein (BCRP) was first described in 1998 in MCF-7 breast cancer cells 
and in human placenta (Doyle et al., 1998), (Allikmets et al., 1998). BCRP consists only of 6 
TM domains and one nucleotide binding domain and is therefore considered as half-transporter. 
Recent studies proposed that BCRP functions as a homodimer (Ozvegy et al., 2001). Like P-gp, 
BCRP shows polarised apical expression in tumour cells but also in normal tissue. BCRP 
expression is found in placenta, breast, ovary, small intestine, colon, blood brain barrier and liver 
(Maliepaard et al., 2001). The location of BCRP indicates its function. In placenta BCRP has a 
major role in the protection of the foetus against drugs, the expression in liver and intestine 
indicates its effects on reducing drug bioavailability and protection against toxins. Substrates of 
Introduction 
20 
BCRP are anticancer agents such as topoisomerase I inhibitors, mitoxantrone, prazosin and the 
food carcinogen PhIP (van Herwaarden et al., 2003), (Jonker et al., 2000), (Cisternino et al., 
2004). BCRP substrates are partly overlapping with P-gp substrates. The amino acid 482 seems 
to be important in recognition of substrates since a SNP on this amino acid leads to resistance to 
known P-gp substrates such as rhodamine 123 or anthracyclines (Robey et al., 2003). 
Clinical importance of BCRP was shown by Kruijtzer et al. by administering topotecan with a 
BCRP-inhibitor. Bioavailability of topotecan increased from 40% to 97% in patients while 
taking the inhibitor (Kruijtzer et al., 2002). This data clearly shows the effect of BCRP in 
limiting drug bioavailability. 
Regulation of BCRP expression in the intestine is not fully elucidated but findings in Caco-2 cell 
lines showed that activation of the aryl hydrocarbon receptor (AhR) is involved (Ebert et al., 
2005). 
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1.3 Regulation of Intestinal Transporters 
Direct functional interaction with transporters in the intestine occurs via a set of different specific 
or unspecific inhibitors. First generation inhibitors of P-gp were developed for other indications. 
The calcium channel blocker verapamil or the immunosuppressant cyclosporine A belong to this 
generation. Unfortunately, these inhibitors are not selective to P-gp, since inhibition of e.g. 
BCRP and CYP3A4 was also described. Second generation drugs are structurally similar drugs to 
the first generation but modified to potentiate the inhibitory ability and to minimise other 
pharmacological effects. However, selectivity to P-gp was not achieved. Dex-verapamil (R-isomer 
of verapamil) and PSC833 (valspodar), a cyclosporine analogue are examples for second 
generation inhibitors. Inhibitors of the third generation have stronger potency and higher 
specificity (Hennessy and Spiers, 2007). 
Besides direct inhibition, modulation of transporters function also can take place via intracellular 
signaling. P-gp function can be reduced or activated by protein kinase C (PKC) isoforms in 
different ways (Sachs et al., 1999). It was shown in hepatocytes that ABC-transporters may reside 
intracellular and are delivered to the canalicular membrane when increased transport function is 
demanded (Kipp and Arias, 2002). Ubiquitination which can determine degradation of proteins 
can also play a role in P-gp modulation. Zhang et al. showed that the ubiquitin-proteasome 
pathway regulates P-gp stability and function (Zhang et al., 2004). Regulation of ABC-
transporter function was described to be influenced by endothelin via the endothelin-B receptor 
(Masereeuw et al., 2000). 
 
1.3.1 Transcriptional Regulation 
The mentioned short-term regulations can take place within minutes and have to be 
distinguished from long-term regulation which affects transcription of ABC-transporters and 
takes place within hours or days. Transcriptional regulation of P-gp is complex and covers many 
different factors which are not yet fully elucidated. Different proteins may bind to the MDR1 
promoter and induce or reduce transcription. The MDR1-promoter, as well as the BCRP-
promoter, lack a TATA-box but contain an initiator element. Several promoter elements have 
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been characterised on the MDR1 and BCRP promoters. (Labialle et al., 2002), (Bailey-Dell et al., 
2001). 
Transcriptional regulation via nuclear receptors is an important regulation of MDR1 and BCRP. 
The nuclear receptors superfamily covers a large amount of structurally related, ligand activated 
transcriptional factors (1999). The subfamily III consists of hormonal receptors such as 
glucocorticoid- (GR), mineralocorticoid- (MR), progesterone- (PR), androstane- (AR) or 
oestrogen receptor (ER). These classic nuclear steroid hormone receptors have high affinity to 
steroids and regulate steroid expression by a negative feedback mechanism of the hypothalamic-
pituary axis. The Subfamily II contains 9-cis retinoic acid receptor (RXR) which forms 
heterodimers with many other nuclear receptors from subfamily I. The latter subfamily comprises 
a large amount of different groups of nuclear receptors. Members of this subfamily are thyroid 
hormone receptor (TR), retinoic acid receptor (RAR), peroxisome proliferator-activated receptor 
(PPAR), liver X receptor (LXR) and vitamin D-receptor like receptors such as vitamin D receptor 
(VDR), pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Several 
members of the nuclear receptor superfamily such as GR, VDR, CAR, PXR and RXR have been 
shown to play a major role in transcriptional regulation of metabolic enzymes and efflux 
transporters (Ogg et al., 1999), (Thummel et al., 2001), (Honkakoski et al., 1998), (Burk et al., 
2005), (Bertilsson et al., 1998), (Geick et al., 2001). 
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Figure 4 Nuclear receptors signal transduction. Ligand binding activates the nuclear receptors CAR or PXR, and 
frees them from co-repressors. In the following, the receptors translocate to the nucleus and build heterodimers 
with RXR. Transcriptional regulation is initiated upon binding to specific response elements of the promoter of 
the target gene. (Timsit and Negishi, 2007) 
 
Among those receptors, PXR and CAR are important for MDR1 regulation. Regulation via PXR 
is of interest in this thesis since many drugs are ligands of PXR (see chapter 1.3.2). BCRP 
expression is not regulated via PXR but other nuclear receptors such as PPARγ (Szatmari et al., 
2006), and aryl hydrocarbon receptor (AhR) (Ebert et al., 2005), (Ebert et al., 2007) or ER 
(Zhang et al., 2006) are described to be involved. 
 
1.3.2 PXR 
The structural organisation of PXR is divided in 4 general domains, a modulator region with 
activation function, a DNA binding domain (DBD) comprising two zinc-finger motifs, a hinge 
region which connects to the ligand binding domain (LBD) which is also associated with an 
activation function. The LBD of PXR is able to bind a variety of different ligands (Watkins et al., 
2001). Such ligands are endogenous and synthetic steroids as well as a variety of different 
xenobiotics such as rifampicin, nifedipine, clotrimazole or paclitaxel (Kliewer et al., 1998), 
(Blumberg et al., 1998), (Lehmann et al., 1998), (Synold et al., 2001). The DBD is conserved 
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among species, sequence homology between human PXR and mouse or rat PXR is 96%, while 
the LBD is less conserved, sequence homology is about 76% (Kliewer et al., 2002). This 
observation might explain the fact that different ligands activate PXR in mouse and human. 
Mechanistic insights in PXR mediated transcriptional regulation revealed ligand binding to the 
inactivated cytoplasmatic nuclear receptor. Then the following sequence of events takes place: 
conformational change, translocation to the nucleus, dimerisation with a co-factor (RXR) and 
final binding to response elements regulates target gene expression (Figure 4). These response 
elements are called xenobiotic response element (XRE) or hormone response element (HRE). 
They are organised as direct- (DR), everted- (ER) or inverted- (IR) repeats, with spacer base pairs 
in-between. These structures allow binding of the DBD of PXR which contains two zinc-finger 
motifs. 
Target genes of PXR are metabolic enzymes and transporters. Several subfamilies of the 
cytochrome P450 (CYP) enzyme family have been shown to be regulated via PXR. Among those 
enzymes CYP3A4 is of special importance, since about 50% of drugs are metabolised by this 
isoform. ABC-transporters, MDR1 and some multi-drug-associated transporters (MRPs) are also 
regulated via PXR. Therefore, the interaction potential on the level of transcriptional regulation 
by PXR is important for drug bioavailability.  
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1.4 Inflammation of the Intestine 
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory disorders of the 
intestinal tract. They are summarised as inflammatory bowel disease (IBD). In UC, the 
inflammation occurs in the mucosa and mucosal ulceration can develop. UC is mainly localised 
in the rectum and spreads to proximal parts of the intestine to a different extent. In CD, any part 
of the gastrointestinal tract can be affected, however the main site of inflammation is the terminal 
ileum and inflammation can occur segmental and discontinuously. In contrast to UC, not only 
the mucosa is affected but also all layers of the intestinal wall and granuloma are formed. The 
pathogenesis of both diseases is not yet fully elucidated. Different factors such as genetics, 
immune dysregulation, the microbial flora in the intestine and barrier dysfunction of intestinal 
epithelial cells may lead to the pathology of IBD. (Kucharzik et al., 2006), (Xavier and Podolsky, 
2007). 
ABC-transporters play an important role in maintaining the barrier function of the intestine, 
therefore their role in IBD is discussed. A downregulation of PXR and MDR1 gene expression in 
UC-patient compared to healthy controls was observed (Langmann et al., 2004). Furthermore, 
mdr1a knock-out mice (mdr1a-/-) were shown to spontaneously develop intestinal inflammation 
with a pathology similar to IBD (Panwala et al., 1998). SNP polymorphism of MDR1 and 
BCRP have been investigated and correlated to IBD. Up to now, it is not known whether there is 
an association between a polymorphism of MDR1 and BCRP and IBD. Different groups could 
not observe this association (Oostenbrug et al., 2006), (Fischer et al., 2007). In contrast to these 
findings, Fiedler et al. revealed an association between UC and the two MDR1 polymorphisms 
G2677T/A and C3435T (Fiedler et al., 2007). A meta-analysis gave an association between 
C3435T and UC, but no association with G2677T/A and none with CD (Annese et al., 2006). 
Therapy options of IBD aim on reduction of inflammation and suppression of immune response. 
Steroids (e.g. budesonide) and 5-aminosalicylates and the immunosuppressants azathioprine and 
methotrexate are standard therapeutics. New options are biologicals such as the anti-TNF-α 
antibody infliximab. Treatment failure with glucocorticoids was described (Farrell and Kelleher, 
2003). Since glucocorticoids are known substrates of P-gp and were shown to induce P-gp gene 
expression via PXR-pathway, the role of P-gp in therapy resistance is discussed. P-gp expression 
Introduction 
26 
was increased in peripheral blood monocytes in UC-patients after glucocorticoid treatment 
(Hirano et al., 2004). Furthermore, treatment failure in UC and CD was associated to an increase 
in P-gp expression in peripheral blood lymphocytes (Farrell et al., 2000). 
Taken together, P-gp might be involved in disease susceptibility due to its barrier function in the 
intestine. Furthermore, it is possibly involved in glucocorticoid resistance due to its function as 
efflux transporter. 
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1.5 Curcuma Longa L. 
Curcuma longa L. belongs to the family of Zingiberaceae (ginger family). It is a perennial plant 
and cultivated in southern parts of Asia. The powdered rhizome of Curcuma longa (turmeric) is of 
importance since it is widely used in food industry as spice and yellow pigment. It also has a long 
tradition in traditional Indian medicine, where it was used as agent to treat inflammatory 
diseases, hepatic disorders and skin wounds (Ammon and Wahl, 1991). 
The main ingredients of Curcuma longa, which are believed to be responsible for its biological 
activities are the curcuminoids curcumin, demethoxycurcumin and bisdemethoxycurcumin. The 
curcuminoids make up about 5% of turmeric powder and the most abundant and best 
investigated is curcumin. In vitro data showed that curcumin interacts with a set of different 
molecular targets such as transcriptional factors, inflammatory cytokines, enzymes, kinases, 
growth factors and receptors. Anti-inflammatory, antioxidant and chemopreventive properties 
were shown for curcumin. Ongoing clinical trials aim to provide treatment of diverse cancer and 
inflammatory diseases (Goel et al., 2008). Treatment of inflammatory disorders in the intestine 
with curcumin is also of special interest. A study in UC-patients showed that curcumin is 
effective in maintaining remission (Hanai et al., 2006). 
After oral intake, curcumin is hardly absorbed and the main part remains in the intestine. 
Interactions on absorption side could be the consequence, since it was described that 
curcuminoids interact with ABC-transporters. In vitro data revealed that the curcuminoids 
modulate P-gp function (Chearwae et al., 2004). A reduced expression of P-gp was also observed 
(Anuchapreeda et al., 2002), (Limtrakul et al., 2004). Inhibition or downregulation of intestinal 
P-gp can affect the intestinal barrier function and increased absorption of xenobiotics could be 
the consequence. Interaction studies with curcumin and BCRP showed that BCRP expression 
was induced by curcumin (Ebert et al., 2007). 
Considering these data curcuminoids could be useful in treatment of inflammatory diseases of the 
intestine but the interaction potential with ABC-transporters has to be determined. 
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2 General Methods 
 
2.1 Cell Culture 
The LS180 and Caco-2 cell lines were purchased from ATCC (Manassas, USA). LS180 and 
Caco-2 cells were cultured in Dulbecco’s MEM with Glutamax-I, supplemented with 10% (v/v) 
fetal bovine serum, 1% non essential amino acids, 1% sodium pyruvate, 50 µg/ml gentamycin 
(Invitrogen AG, Basel, Switzerland). Caco-2 clones additionally were treated with geneticin 
(Invitrogen) 1 mg/ml as selection antibiotic. Cells were maintained in a humidified 37°C 
incubator with a 5% carbon dioxide in air atmosphere.  
 
2.2 Reverse Transcription, real time PCR (Taqman) 
LS180 and Caco-2 cells were disintegrated by adding lysis buffer RLT (Qiagen, Hilden, 
Germany) and homogenised by using QIAshredder columns (Qiagen). Total RNA was extracted 
from cell lysates using the RNeasy Mini Kit (Qiagen). RNA was quantified with a Nanodrop 
Spectrophotometer (Witeg AG, Littau-Luzern, CH). The purity of the RNA preparations was 
high as demonstrated by the 260 nm / 280 nm ratio (range 1.8-2.1). After DNase I digestion 
(Gibco, Life Technologies, Basel Switzerland) 0.75 µg of total RNA was reversed transcribed by 
Superscript II (Gibco) according to the manufacturer’s protocol using random hexamers as 
primers (Applied Biosystems, Rotkreuz, Switzerland).  
TaqMan analysis was carried out on a 7900HT Sequence Detection System (Applied 
Biosystems). PCR conditions were 10 min 95°C followed by 40 cycles of 15 s 95°C and 1 min 
60°C. Each TaqMan reaction contained 10 ng of cDNA in a total volume of 10 µL. qPCRTM 
Mastermix Plus from Eurogentec (Seraing, Belgium) was used. Primers and probes were used at 
concentrations of 900 nM and 225 nM, respectively. They were synthesised by Invitrogen (Basel, 
Switzerland) and by Eurogentec (Seraing, Belgium), respectively. Primers and probes were 
designed according to the guidelines of Applied Biosystems with help of the Primer Express 2.0 
software. Corresponding sequences of primers and probes for TaqMan analysis are shown in 
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Table 1. All samples were run in triplicates and not reverse-transcribed RNA served as a negative 
control. 
For absolute quantification we used external standard curves. Standards were gene-specific cDNA 
fragments that cover the TaqMan primer/probe area and they were generated by PCR. Sequences 
of the corresponding primers are shown in Table 2. The PCR products were purified by running 
a 1.5% agarose gel and a subsequent gel extraction (gel extraction kit, Qiagen). The standards 
were quantified using the PicoGreen reagent (Molecular Probes, Eugene, OR, USA) and were 
checked by sequencing (Microsynth GmbH, Balgach, Switzerland). For some genes there were 
used cDNA samples to generate a standard curve. 
 
Table 1 Primers and Probes for TaqMan Analysis 
Gene Probe 
GAPDH 5`-CGCCTGGTCACCAGGGCTGC-3` 
MDR1 5`-AAGCTGTCAAGGAAGCCAATGCCTATGACTT-3` 
BCRP 5`-CCATTGCATCTTGGCTGTCATGGCTT-3` 
GR alpha 5`-TTTCAACCACTTCATGCATAGAAT-3` 
GR beta 5`-CATAACATTTTCATGCATAGAATCCAAGAGTTTTGTCA-3` 
PXR 5`-AGCCCTTGCATCCTTCACATGTCATGA-3` 
CYP3A4 5`-TTCTCCTGGCTGTCAGCCTGGTGC-3` 
CYP1A2 5`-CACAGCCATCTCCTGGAGCCTCATGTA-3` 
COX-2 5`-TTCCTACCACCAGCAACCCTGCCA-3` 
5-LOX 5`-CTTCGAGCGTGGCGCGGTG-3` 
TNF-alpha 5`-TAGCCCATGTTGTAGCAAACCCTCAAGCT-3` 
Il-8 5`-CTTGGCAAAACTGCACCTTCACACAGA-3` 
iNOS 5'-TGGCAAGCACGACTTCCGGGTG-3' 
 
General Methods 
30 
Gene Forward Primer (FW) and Reverse Primer (REV) 
GAPDH FW: 5`-GGTGAAGGTCGGAGTCAACG-3` 
REV: 5`-ACCATGTAGTTGAGGTCAATGAAGG-3` 
MDR1 FW: 5`-CTGTATTGTTTGCCACCACGA-3` 
REV: 5`-AGGGTGTCAAATTTATGAGGCAGT-3` 
BCRP FW: 5`-CAGGTCTGTTGGTCAATCTCACA-3` 
REV: 5`-TCCATATCGTGGAATGCTGAAG-3` 
GR alpha FW: 5`-GGCAGCGGTTTTATCAACTGA-3` 
REV: 5`-AATGTTTGGAAGCAATAGTTAAGGAGA-3` 
GR beta FW: 5`-AACTGGCAGCGGTTTTATCAA-3` 
REV: 5`-TGTGAGATGTGCTTTCTGGTTTTAA-3` 
PXR FW: 5`-GGCCACTGGCTATCACTTCAA-3` 
REV: 5`-GTTTCATGGCCCTCCTGAAA-3` 
CYP3A4 FW: 5`-TCTCATCCCAGACTTGGCCA-3` 
REV: 5`-CATGTGAATGGGTTCCATATAGATAGA-3` 
CYP1A2 FW: 5`-CAATGACGTCTTTGGAGCAGGAT-3` 
REV: 5`-CAATCACAGTGTCCAGCTCCTTC-3` 
COX-2 FW: 5`-GAATCATTCACCAGGCAAATT-3` 
REV: 5`-TTTCTGTACTGCGGGTGGAAC-3` 
5-LOX FW: 5`-TGGACAAGCCCTTCTACAACG-3` 
REV: 5`-CTCGTCCACAGTCACGTCGT-3` 
TNF-alpha FW: 5`-TCTTCTCGAACCCCGAGTGA-3` 
REV: 5`-CCTCTGATGGCACCACCAG-3` 
Il-8 FW: 5`-CTCTTGGCAGCCTTCCTGATT-3` 
REV: 5`-TATGCACTGACATCTAAGTTCTTTAGCA-3` 
iNOS FW: 5'-TGCAGACACGTGCGTTACTCC-3' 
REV: 5'-GGTAGCCAGCATAGCGGATG-3' 
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Table 2 Primers for cDNA Standards 
Gene Forward Primer Reverse Primer 
GAPDH 5`-ACATCGCTCAGAACACCTATGG-3` 5`-GCATGGACTGTGGTCATGAGTC-3` 
MDR1 5`-ACAGTCCAGCTGATGCAGAGG-3` 5`-CCTTATCCAGAGCCACCTGAAC-3` 
BCRP 5'-TTTCAGCCGTGGAACTCTTT-3' 5'-TGAGTCCTGGGCAGAAGTTT-3' 
GR alpha 5`-TACCCTGCATGTACGACCAA-3` 5`-TTTTGGTATCTGATTGGTGATGA-3` 
GR beta 5`-TACCCTGCATGTACGACCAA-3` 5`-TTGTCGATGAGCATCAGTTG-3` 
PXR 5`-GCAGTCCAAGAGGCCCAGAA-3` 5`-CGTCGGACATGATCATCTCCTTC-3` 
CYP3A4 5'-TAGTGATGGCTCTCATCCCAGA-3' 5'-TGAAGGTTGGAGACAGCAATGA-3' 
CYP1A2 5'-ACTTTGACAAGAACAGTGTCCGG-3' 5'-GCCAAACAGCATCATCTTCTCA-3' 
COX-2 5`-CATAGGGCTTCAGCATAAAGCG-3` 5`-ACCCTCTATCACTGGCATCCC-3` 
 
2.3 Western Blot 
Proteins were extracted with protein extraction buffer (20 mM Tris-HCl, 1% Igepal CA-630, 0.5 
mM sodium orthovanadate) including 1 mM of the protease inhibitor phenylmethylsulfonyl 
fluoride (Sigma-Aldrich, St. Louis, MO, USA) and protease inhibitor cocktail tablet, Complete 
Mini (Roche Diagnostics, Germany). The quantification of the protein content was performed 
with the BCA protein assay kit (Pierce Chemical, Rockford, IL, USA). Protein concentration was 
determined by measuring the absorbance at 562 nm with Spectra MAX 250 Microplate 
Spectrophotometer (Molecular Devices Corporation, California, USA). 
For immunoblotting, 50 µg of total protein extract was mixed with Laemmli sample buffer (Bio 
Rad Laboratories, Reinach, Switzerland) and transferred to the polyacrylamide gel. Gel 
electrophoresis was performed with a Mini Protean 3 Electrophoresis Cell (Bio Rad) applying 80 
V for 15 min for the stacking gel (4% acrylamide) and 120 V for 1 hour for the separating gel 
(6.5-10% acrylamide). After electrophoresis, proteins were blotted to the nitrocellulose 
membrane (250 mA for 2.5 hours) using a Mini Trans-Blot Cell (Bio Rad). Protein transfer was 
verified by Ponceau S staining. The membrane was blocked overnight at 4°C with PBS 
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containing 5% milk powder and 0.05% Tween 20. After washing three times for 15 minutes 
(0.05% Tween in PBS), the membrane was incubated for 2 hours at room temperature with the 
respective primary antibody in PBS containing 0.05% Tween and 1% milk powder. As loading 
control beta-actin mouse monoclonal antibody (abcam, Cambridge, UK) was used. After the first 
incubation the membrane was washed 3 times for 15 min and then incubated with the secondary, 
horseradish peroxidase-conjugated, rabbit anti-mouse or goat anti-rabbit IgG (Amersham, 
Buckinghamshire, UK) diluted 1:1000. Secondary antibody incubation was performed for 1 hour 
at room temperature. Membranes were washed, and protein detection was performed with the 
enhanced chemiluminescence system (ECL-Detection-Kit, Amersham). The molecular weight 
was identified by using Precision Plus ProteinTM Standard Dual Color (Bio Rad).  
Table 3 Antibodies 
Protein Antibody Concentration (Dilution) 
MDR1 C219 (Alexis Corporation, Lausen, CH) 0.1 mg/ml (1:100) 
BCRP BXP-21 (Alexis) 0.25 mg/ml (1:100 – 1:1000) 
PXR PXR Rabbit Polyclonal Antibody 
(abcam, Cambridge, UK) 
0.53 mg/ml (1:500) 
Beta-actin mouse monoclonal antibody (abcam) 1 mg/ml (1:1000 – 1:10000) 
 
2.4 Transport 
Caco-2 cells were seeded on type I collagen 5 µg/cm2 (Becton Dickinson, Basel, CH) precoated 
Transwell® filters (polycarbonate 12 well, pore size 0.4 μm or polyester [clear], 12 well, pore size 
0.4 μm) (Corning, Baar, Switzerland) in a density of 660‘000 cells/cm2. Cells were cultured for 3 
days in DMEM high glucose (see chapter 2.1). After 2 or 3 days medium was changed. Cells were 
incubated with Intestinal Epithelial Differentiation Medium (BD) and 0.1% MITO+ Serum 
Extender (BD). On the 4th or 5th day, medium was exchanged again and on the 5th or 6th day the 
transport-assay was performed. 
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Before starting the assay, both sides of the Transwell® were washed 3 times with pre-warmed 
HBSS (Gibco) supplemented with 1mM pyruvate and 10 mM Hepes adjusted to a pH of 7.4 
(HBSS-P). A pre-incubation with or without the respective inhibitor dissolved in HBSS-P on the 
apical side (0.5 ml) and HBSS-P at the basolateral side (1.5 ml) was performed for 15 minutes. 
For apical-to-basolateral (AB) transport, at time t=0 substrates and tightness-marker with or 
without inhibitor were given to the apical donor chamber and on the basolateral donor 
compartment HBSS-P was added. Transport was performed at 37°C and 120 rpm over 2 hours. 
Samples were taken after 10, 20, 40, 60, 90 and 120 minutes out of the basolateral donor 
compartment. Volume was replaced with HBSS-P. For basolateral-to-apical (BA) transport, the 
basolateral side acted as donor chamber and the apical side was the acceptor chamber. Thus, 
substrate and tightness-marker were added to the basolateral side and samples were taken out of 
the apical side. However, if an inhibitor was used, it was added to the apical acceptor 
compartment. Samples were taken at indicated time points out of the acceptor compartment 
(apical) and volume was replaced.  
After 2 hours, samples out of the donor chamber were also taken for drawing the balance of 
transport. Transport-buffer was removed and the Transwell® was placed on ice. Both sides of the 
Transwell® were washed 3 times with ice-cold HBSS-P. Transwell®-filters were cut for 
measurement of the remaining substance in the cells. Radioactive-labeled (14C or 3H) or 
fluorescent substrates were used. Insta Gel plus scintillation liquid was added to the radioactive 
samples and analysis was performed on a scintillation counter (Packard TriCarb2000, Canberra 
Packard S.A.). Detection of fluorescent samples was carried out on a fluorescent reader (HTS 
7000 Plus Bioassay Reader, Perkin Elmer Ltd., Buckinghamshire, UK). To confirm tightness of 
the monolayer 14C-sucrose (0.6 µCi/ml) (Perkin Elmer, Schwerzenbach, Switzerland) or Lucifer 
Yellow (20 µM) (Sigma Aldrich, Buchs, CH) was used. LY was measured at 428 nm excitation 
and 536 nm emission. 
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The apparent permeability coefficient (Papp) was calculated for tightness-markers in order to 
determine the tightness of the monolayers. Papp is calculated with the following equation: 
 
The term  is the steady-state flux, A stands for the surface of the filter and C0 is the initial 
concentration of the donor chamber (Hubatsch et al., 2007). 
 
2.5 Uptake 
Cells were seeded 50’000 cells/cm2 on 24-well plates (Falcon) and incubated for 2-3 weeks and 
medium was changed every 3-4 days (chapter 2.1). Before starting the assay, cells were washed 3 
times with pre-warmed HBSS supplemented with 1 mM pyruvate and 10 mM Hepes (HBSS-P) 
and incubated for 15 min at 37°C and 120 rpm with HBSS-P with or without inhibitor. After 
this pre-incubation cells were incubated with the respective substrate with or without inhibitor 
for the indicated time. In this step influx and efflux of the substrate goes on, while in the cells 
where an inhibitor is added, the efflux is inhibited. After this period of time the plate was placed 
on ice and samples of the supernatant were taken. Cells were washed 3 times with ice cold HBSS-
P with or without inhibitor. In order to achieve cell-lysis, 5% Triton X-100 was added and cells 
were incubated again for 1 hour. The lysate was homogenised and samples were taken for 
measurement of the remaining substance in the cells. Radioactive-labeled (14C or 3H) compounds 
were given to Insta Gel plus scintillation liquid and analysis was performed on a scintillation 
counter (Packard TriCarb2000, Canberra Packard S.A.). Fluorescent compounds were analysed 
on a fluorescent reader (HTS 7000 Plus Bioassay Reader, Perkin Elmer Ltd.). 
 
2.6 Efflux 
Cells were seeded and cultured as described for the uptake assay. All monolayers were washed 3 
times with pre-warmed HBSS-P (37°C) and were pre-incubated for 15 min at 37°C and 120 rpm 
with corresponding inhibitors dissolved in HBSS-P. The solutions were removed and all cells 
were incubated with HBSS-P containing the test-compounds and corresponding inhibitors for 30 
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min at 37°C and 120 rpm. After loading the plate was put on ice and the cells were washed 3 
times with ice-cold HBSS-P with or without the test inhibitors. Subsequently HBSS-P (37°C) 
alone and with inhibitors was added to the cells, and the efflux took place the indicated time at 
37°C and 120 rpm. After this period of time, the reaction was stopped by putting the plate on ice 
and samples from the supernatant were taken for measurement of efflux. Afterwards, cells were 
rinsed 3 times with ice cold HBSS-P with or without inhibitors. Then, they were lysed at 37°C 
for approximately 1 hour using 5% Triton-X. Cells, which were treated with radioactive labeled 
compounds, were transferred to scintillation vials. After adding Insta Gel plus, the samples were 
analysed in a scintillation counter (Packard TriCarb2000). The cells loaded with fluorescent 
drugs were analysed on a Perkin-Elmer HTS 7000 Bio Assay Reader using the indicated settings.  
 
2.7 Statistics 
If not otherwise stated, groups were compared to control group by analysis of variance 
(ANOVA). If this analysis revealed significant differences and more than one treatment group 
was included in the analysis, pairwise comparisons of treatment groups with the control group 
was performed subsequently using Dunnett’s two-sided multi-comparison test. All tests were 
performed using the SPSS for Windows software (version 15.0). The level of significance was 
P<0.05.  
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3 Knock-down (Silencing) of ABC-Transporters 
 
3.1 Establishment of the Silencing Method 
3.1.1 Abstract  
Background and Purpose: RNA knock-down or silencing is a new method to inhibit protein 
expression by cutting mRNA sequence specifically. P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP) are two important ATP-binding cassette transporters (ABC-
transporters) in the intestine. They are expressed at relatively high levels at the apical membrane 
of enterocytes and figure as efflux transporters of various drugs and toxins. Highly specific 
chemical inhibitors of P-gp and BCRP are lacking. Therefore, we aimed to establish an intestinal 
cell culture model with selective knock-down of P-gp and BCRP and with concomitant knock-
down of both (co-silencing). 
Experimental Approach: Specific sequences for P-gp and BCRP silencing were designed using an 
open access algorithm, synthesised and integrated into the pSUPER vector. Caco-2 cells were 
transfected with these vectors containing a neomycin resistance gene for selection. Stable clones 
were achieved by culture under antibiotic pressure. Validation of the specific knock-down of the 
silencing clones was performed on mRNA level by real-time RT-PCR and on protein level by 
Western blot analysis. Functional inhibition of P-gp and BCRP was measured using efflux and 
transport assays with the specific P-gp substrates 3H-digoxin and rhodamine 123 (R123), and the 
specific BCRP substrate 14C-PhIP. 
Key Results: Stable knock-down of P-gp on mRNA level was achieved by reducing mRNA 
expression 75% and 95% in P-gp- and co-silencing clones compared to control. Knock-down of 
BCRP yielded a reduction of 90% and 80% mRNA expression in BCRP- and co-silencing 
clones, respectively. On protein level, no P-gp could be detected in the P-gp- and co-silencing 
clones. BCRP protein was not detectable as dimer in BCRP- and co-silencing clones but the 
monomer was still as detectable as in the controls. Transport assays from apical-to-basolateral 
(AB) through Caco-2 monolayers with 3H-digoxin revealed significantly higher transport rates 
when P-gp was silenced or inhibited with verapamil. In addition, remaining R123 in the efflux 
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assays showed functional inactive P-gp in the P-gp-silencing clone. Transport assays AB of 14C-
PhIP, a substrate of BCRP, also showed significant higher transport rates when BCRP was 
silenced or inhibited with prazosin. Efflux assays with PhIP also showed functional inactive 
BCRP in the BCRP-silencing clone. 
Conclusions and Implications: A stable intestinal cell culture model with a selective knock-down 
of P-gp and BCRP was established. Using this system with single and concomitant knock-down 
of P-gp and BCRP, the impact of each transporter on substrates, which are transported by both 
ABC-transporters, could be determined. 
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3.1.2 Introduction 
Silencing or RNA interference (RNAi) is a sequence specific knock-down of genes, which is based 
on the target specific recognition of the messenger RNA (mRNA) and its following cleavage. 
RNAi was suggested to be important for the protection of the genome against mobile genetic 
information such as viruses or transposons. Silencing first was observed in pigmented Petunia 
plants in 1990 and was termed post-transcriptional-gene-silencing (PTGS). In a transfection 
experiment, intending to over-express the chalcone synthase for achieving more purple petunias, 
the contrary effect was observed. Transgenic petunias showed less mRNA expression of chalcone 
synthase (Napoli et al., 1990). In 1992, it was shown, that exogenous genes transfected into 
Neosporum crassa could inactivate sequence specifically the corresponding endogenous gene. 
This observation was named ‘quelling’ (Romano and Macino, 1992). First insights in the 
mechanism of silencing was given by Fire et al. who could demonstrate that double-stranded 
RNA (dsRNA) silenced the corresponding gene in Caenorhabditis elegans (C. elegans) (Fire et 
al., 1998). Later on, siRNA (small interfering RNA) consisting of ~25 nucleotides dsRNA were 
identified as main component of gene silencing (Hamilton and Baulcombe, 1999). Zamore et al. 
identified even smaller siRNA of 21- to 23- nucleotides, which cleaves the target mRNA in 21- to 
23-nt intervals (Zamore et al., 2000). This processing of dsRNA to siRNA in the cytoplasm is 
catalysed by a nuclease of the RNAse III class and was called Dicer (DCR) (Bernstein et al., 
2001). Elbashir et al. revealed that 21- and 22- nucleotide sense and antisense strand with 2 
nucleotides overhang at the 3’- terminal are the main actors of RNAi. Using chemically 
synthesised siRNA, they showed that siRNA can be uncoupled from dsRNA and functional gene 
silencing in mammalian cells can be achieved with synthetic siRNA (Elbashir et al., 2001). 
These siRNAs are then further incorporated into a nuclease-complex which was named RNA-
induced-silencing-complex (RISC) (Hammond et al., 2000). Martinez et al found that the siRNA 
double-strand is unwounded and a single-strand remains in the RISC. This single-strand should 
match to the target mRNA so that the nuclease is able to cleave the target mRNA (Martinez et 
al., 2002). The strand which is less strong bound to the complementary strand at his 5’-end is 
preferentially inserted into the RISC. Therefore, the antisense strand which fits to the target 
mRNA should have a weaker 5’- end (Schwarz et al., 2003). The cleavage position was suggested 
Establishment of the Silencing Method 
39 
to be in the middle of this ~21nt siRNA, Elbashir et al. proclaimed that the cleavage position is 
located 7-10nt downstream of the 5’-terminus (Elbashir et al., 2001) (Figure 5). 
 
 
Figure 5 Critical steps in the RNAi mechanism. shRNA is first cut to siRNA and then incorporated into the RISC. 
Incorporation of the antisense strand leads to target cleavage, while incorporation of the sense strand leads possibly to 
inefficient or non-specific effects (Huppi et al., 2005). 
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With this information about the conditions for a knock-down of genes, several in vitro assays for 
targeted silencing were established. One of these methods is the plasmid-based stable transfection 
of silencing sequences. The target specific DNA sequence which is incorporated into a plasmid 
forms after transcription a short-hairpin-RNA (shRNA) and is as effective as synthetic siRNA. 
Brummelkamp et al. designed the pSUPER-vector which was used in our studies (Brummelkamp 
et al., 2002). 
We aimed to establish an intestinal cell system with a stable and selective knock-down of the 
ABC-transporters P-glycoprotein (P-gp, MDR1, ABCB1) and breast cancer resistance protein 
(BCRP, ABCG2), as well as of both transporters simultaneously. The lack of defined high 
specific chemical inhibitors for the respective transporters was the rationale to establish this 
system for intestinal transport studies. These two transporters form an important intestinal barrier 
for various xenobiotics. A knock-down of either P-gp or BCRP has the potential to influence the 
bioavailability of several drugs.  
 
Table 4: Silencing terms 
RNAi  RNA interference: 
Regulatory mechanism of gene expression. Inhibition of gene expression via mRNA degradation by 
a complementary dsRNA (or siRNA, shRNA). 
The natural function of RNAi is supposed to be protection of the genome against e.g. viruses.  
dsRNA  Double-stranded RNA:  
Long RNA duplexes which trigger RNAi within the region of homology to mRNA sequences. 
Intracellular they are cut in 21–23-nt RNA fragments which recognise the target mRNA. 
siRNA  small interfering RNA:  
A short double-stranded RNA molecule of ~21nt size that effects RNAi 
shRNA short hairpin RNA: 
DNA of the target gene inserted into a vector which is intracellular transcribed to a hairpin RNA 
and subsequently processed to siRNA. 
DCR  Dicer: 
A nuclease of the RNase III family which cleaves dsRNA to 20-25 nucleotides in length with 3’ 
overhangs of 2 to 3 nucleotides. 
RISC  RNA induced silencing complex: 
A complex of different proteins which have a nuclease activity. These proteins assemble with the 
siRNA and are responsible for the target specific cleavage of the mRNA. 
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3.1.3 Methods 
Materials 
3H-Digoxin (9 Ci/mmol) and 14C-sucrose (588 mCi/mmol) was purchased from Perkin Elmer 
AG (Schwerzenbach, CH). 14C-PhIP (10 mCi/mmol) was from Toronto Research Chemicals Inc. 
(Toronto, Ontario, Canada). Lucifer Yellow (LY) (Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in phosphate buffered saline (PBS) (Invitrogen, Basel, CH). Prazosin (Sigma-Aldrich) 
was dissolved in DMSO. Verapamil (Sigma-Aldrich) was dissolved in water. Rhodamine 123 
(Molecular Probes, Eugene, OR, USA) was dissolved in ethanol.  
 
Design of shRNA 
ABCB1 (MDR1) (Acc.No. NM_000927) and ABCG2 (BCRP) (Acc. No. NM_004827) shRNA 
sequences were designed using the siRNA design algorithm of Whitehead Institute for 
Biomedical Research (http://jura.wi.mit.edu/bioc/siRNAext/home.php). A sequence pattern 
based on investigations of Reynolds et al. was chosen (Reynolds et al., 2004). This siRNA pattern 
consists of the sequence N4AN6TN2HN5WN2, while N= any nucleotide, H= A, T or C, W= A 
or T (following the Nomenclature for Incompletely Specified Bases in Nucleic Acid Sequences, 
Nomenclature Committee of the International Union of Biochemistry, NC-IUB). Further 
parameters for the siRNA search were a GC percentage from 30 to 70%, no sequence with 4 or 
more T, A or G in a row, only less than 7 consecutive GC in a row and a siRNA-ending with 
TT. Among the proposed siRNA sequences, siRNA were chosen which lay in the open reading 
frame (ORF) and which exhibit a negative thermodynamic value (ΔG = ΔG 5’-sense-strand – ΔG 
5’-antisense-strand) (Schwarz et al., 2003), (Khvorova et al., 2003). These sequences were then 
aligned using the NCBI Blast tool. The thermodynamic profile of these designed sequences was 
checked using the iRNAi program (http://mekentosj.com/irnai/). This program suggests 
sequences for the forward and reverse strand which contain the selected siRNA sequence, 
nucleotides for the loop of the shRNA and nucleotides at the end which fit into the pSUPER-
vector digested with the restriction enzymes BglII and HindIII. For both genes, MDR1 and 
BCRP, one sequence was chosen. Additionally, other sequences earlier described in literature were 
used as positive control (Celius et al., 2004), (Li et al., 2005). As negative control, a functional 
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and targeting sequence with an inaccurate thermodynamic profile was chosen for both genes. 
Under these conditions, the RISC should incorporate the sense-strand of the siRNA and no 
silencing effect should be provoked. Secondly, a non-targeting but functional sequence was taken. 
This sequence was described earlier by Taniguchi et al. (Taniguchi et al., 2006). Sequences for the 
shRNA are listed in Table 5.  
Table 5: Sequences for shRNA 
 
MDR1 human, Acc. No: NM_000927 
siMDR1h1 
Target sequence 5`-AAGGCCTAATGCCGAACACATTG-3` 
Reference Celius T, Biochem Biophys Res Commun. 2004:5;324:365-71 
Sequence for pSUPER FW: 5`-GATCCCC GGCCTAATGCCGAACACAT TTCAAGAGA 
ATGTGTTCGGCATTAGGCC TTTTTGGAAA-3` 
RV: 5`-AGCTTTTCCAAAAA GGCCTAATGCCGAACACAT 
TCTCTTGAA ATGTGTTCGGCATTAGGCC GGG-3` 
 
siMDR1h2 
Target sequence 5`-TTGGAGGATTATGAAGCTAAATT-3` 
Reference - 
Sequence for pSUPER FW: 5`-GATCCCC GGAGGATTATGAAGCTAAA TTCAAGAGA 
TTTAGCTTCATAATCCTCC TTTTTGGAAA-3 
RV: 5`-AGCTTTTCCAAAAA GGAGGATTATGAAGCTAAA 
TCTCTTGAA TTTAGCTTCATAATCCTCC GGG-3 
 
siMDR1h3 neg 
Target sequence 5`-TGATAAAGAACTCTTAGCGTATG-3` 
Reference - 
Sequence for pSUPER FW: 5`-GATCCCC ATAAAGAACTCTTAGCGTA TTCAAGAGA 
TACGCTAAGAGTTCTTTAT TTTTTGGAAA-3 
RV: 5`-AGCTTTTCCAAAAA ATAAAGAACTCTTAGCGTA 
TCTCTTGAA TACGCTAAGAGTTCTTTAT GGG-3 
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BCRP human, Acc. No: NM_004827: 
siBCRPh1 
Target sequence 5`-AAGGTTGGAACTCAGTTTATCCG-3` 
Reference Li WT, Neoplasma. 2005;52:219-24 
Sequence for pSUPER FW: 5`-GATCCCC GGTTGGAACTCAGTTTATC TTCAAGAGA 
GATAAACTGAGTTCCAACC TTTTTGGAAA-3` 
RV: 5`-AGCTTTTCCAAAAA GGTTGGAACTCAGTTTATC 
TCTCTTGAA GATAAACTGAGTTCCAACC GGG-3` 
 
siBCRPh2 
Target sequence 5`-GTGGAGGCAAATCTTCGTTATTA-3` 
Reference - 
Sequence for pSUPER FW: 5`-GATCCCC GGAGGCAAATCTTCGTTAT TTCAAGAGA 
ATAACGAAGATTTGCCTCC TTTTTGGAAA-3` 
RV: 5`-AGCTTTTCCAAAAA GGAGGCAAATCTTCGTTAT 
TCTCTTGAA ATAACGAAGATTTGCCTCC GGG-3` 
 
siBCRPh3 neg 
Target sequence 5`-TGTAATTCAGGTTACGTGGTACA-3` 
Reference - 
Sequence for pSUPER FW: 5`-GATCCCC TAATTCAGGTTACGTGGTA TTCAAGAGA 
TACCACGTAACCTGAATTA TTTTTGGAAA-3` 
RV: 5`-AGCTTTTCCAAAAA TAATTCAGGTTACGTGGTA 
TCTCTTGAA TACCACGTAACCTGAATTA GGG-3` 
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Negative control, scrambled sequence: 
siscrambled 
Target sequence 5'-GCTATCGCTACGTGTAAGT-3' 
Reference Taniguchi H, Development. 2006;133:1923-31 Supplementary Material 
Sequence for pSUPER FW: 5'-GATCCCC GCTATCGCTACGTGTAAGT TTCAAGAGA 
ACTTACACGTAGCGATAGC TTTTTGGAAA-3' 
RV: 5'-AGCTTTTCCAAAAA GCTATCGCTACGTGTAAGT 
TCTCTTGAA ACTTACACGTAGCGATAGC GGG-3' 
 
Plasmid Preparation 
pSUPER-vector was digested with the restriction enzymes BglII and HindIII (Fermentas Inc., 
Ontario, Canada). On a 1% agarose gel the resulting two sequences were separated and the 
opened plasmid was extracted using QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s protocol. The previously described designed sequences were synthesised by 
Invitrogen (Invitrogen AG, Basel, CH). The forward and reverse strand were annealed and 
afterwards ligated into the pSUPER-vector (OligoEngine, Seattle, USA) at the BglII and HindIII 
sites with T4 DNA ligase (Fermentas).  
These plasmids were transformed into Sure®2 Supercompetent cells (Stratagene, La Jolla, CA, 
USA) following the manufacturers protocol. Bacteria were then plated on a LB-Ampicillin-Agar 
(ampicillin 100 µg/ml) overnight at 37°C. The following day, clones were picked and again let 
grown on a control LB-Ampicillin-Agar plate and in 2ml LB-Ampicillin-Medium overnight at 
~240 rpm at 37°C. Plasmid isolation was performed following the protocol Nucleospin® Plasmid 
(Macherey-Nagel, Oensingen, CH).  
The obtained plasmids were checked with a control digestion using HindIII and XbaI restriction 
enzymes (Fermentas Inc., Ontario, Canada). When correctly ligated we obtained two fragments 
with the size of ~4400 bp and 313 bp, which was analysed on an agarose gel. A sequencing 
analysis was performed by microsynth (Microsynth AG, Balgach, CH) using T3 seq primer.  
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Clones containing correct plasmid sequences were grown again overnight at 37°C in 250 ml LB-
Ampicillin-Medium at ~240 rpm. Plasmid isolation was performed with the Nucleobond® 
AX500 Kit (Macherey-Nagel, Oensingen, CH) following the protocol. 
 
Transfection and Generation of Stable Caco-2-Silencing Clones 
Caco-2 cells were transfected using LipofectamineTM 2000 (Invitrogen). For transient 
transfection, cells were seeded on 12-well plates and transfection was started when cells reached 
confluence of ~60%. Transfection was performed following the manufacturers protocol using 2 
µg Plasmid DNA and 4 µl LipofectamineTM 2000 each in a volume of 100 µl Opti-MEM I 
(Invitrogen) and 1 ml DMEM without gentamycin per well. RNA extraction was carried out 
after different time points after transfection.  
For stable transfection, 1 day before transfection, Caco-2 cells were seeded on 6-well-plates in 
Dulbecco’s modified Eagle’s medium with Glutamax-I, supplemented with 10% fetal bovine 
serum, 1% non-essential amino acids, 1% sodium pyruvate, 50 µg/ml gentamycin. Transfection 
was started when cells reached a confluence of ~60%. Transfection was performed following the 
manufacturers protocol using 4 µg Plasmid DNA and 10 µl LipofectamineTM 2000 each in a 
volume of 250 µl Opti-MEM I and 2 ml DMEM without gentamycin per well. In the case of co-
silencing, both plasmids, siMDR1h2 and siBCRPh2, were mixed in the same proportion and 
transfected into the cells. For obtaining stable clones, cells were diluted 1:40 into 10 mm Petri 
dishes after 72 hours and the selection antibiotic geneticin (Invitrogen) was added in a 
concentration of 1.5 mg/ml. Every 3-4 days DMEM with geneticin was replaced. After 2 weeks 
clones were picked using Scienceware® Cloning discs (Sigma-Aldrich) and further cultured in 24-
well plates with a geneticin concentration of 1 mg/ml. 
Each clone was passaged over 6 passages and mRNA expression of the gene of interest was 
performed. The best silencing clone was chosen for further experiments. Evaluation of the 
silencing clones was performed on mRNA level using real time RT-PCR (Taqman), on protein 
level by western blot analysis and on activity level using different functional assays such as uptake-
, efflux- and transport-assay. These methods as well as cell culture conditions are described in 
chapter 2. 
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3.1.4 Results 
Transient Transfection 
mRNA Expression of MDR1 and BCRP 
MDR1 and BCRP silencing plasmids were transfected into Caco-2 cells and mRNA expression 
was measured after transfection. Best silencing effects with MDR1-silencing clones were achieved 
after 24 or 48 hours. The plasmids siMDR1h1, siMDR1h2 and siMDR1h3 showed 40-50% 
reduction of MDR1 mRNA expression whereas the negative control (siscrambled) did not 
significantly alter MDR1 mRNA expression. As a further control experiment, effects of BCRP 
silencing plasmids on MDR1 mRNA expression were analysed. The introduction of siBCRP 
plasmids had no reducing effect on the level of MDR1 mRNA expression (Figure 6A).  
On the other hand, 96 hours after transfection with siBCRP plasmids (siBCRPh1,h2,h3) BCPR 
mRNA expression was reduced to a level of 60-70% compared to control. Transfection of the 
negative control (siscrambled) resulted in a 10% reduced BCRP mRNA expression level, however 
this effect was not significantly different compared to control. The MDR1 silencing plasmid 
siMDR1h1 exhibited a 40% reduction on BCRP mRNA expression, whereas siMDR1h2 showed 
no significant reduction in BCRP mRNA expression (Figure 6B).  
The negative control siMDR1h3 and siBCRPh3 showed, despite their inaccurate thermodynamic 
profile, effects on the expression levels of the respective transporters and where therefore not used 
for further experiments (Figure 6A and B).  
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Figure 6 mRNA expression of MDR1 (A) and BCRP (B) after transfection with silencing plasmids. mRNA 
expression was measured after 96 hours (except A: siMDR1h1-3 after 48 hours) and determined by quantitative real-
time PCR. Results are normalised to control cells and expressed as mean ± s.e.m. (n=3). *p < 0.05, **p < 0.01 ***p < 
0.001 vs. control cells. 
 
Stable Transfection 
mRNA Expression of MDR1 and BCRP 
Several clones were cultivated over 6 passages and mRNA was extracted in every passage. The best 
clones were chosen according to the best silencing effect of the desired gene and to the absence of 
silencing effects on the other gene. The chosen clones contained the sequences siMDR1h2, 
siBCRPh2 and siscrambled. Data of mRNA expression of these clones are shown in Figure 7.  
Silencing of MDR1 mRNA expression was achieved up to 75% in the single siMDR1-
transfection and up to 95% in the co-silencing clone (cosil), where both siMDR1 and siBCRP 
were transfected at the same time. The BCRP-silencing clone, siBCRP, and the negative control, 
siscrambled, exhibited no significant effects on MDR1 mRNA expression. 
BCRP silencing effects on mRNA level were achieved with the single BCRP-transfection, 
siBCRP, up to 90% and in the co-silencing transfection up to 80%. Unfortunately, the siMDR1-
clone and the negative control also reduced BCRP mRNA expression about 25% percent. 
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Figure 7 mRNA expression of MDR1 (A) and BCRP (B) in stable silencing clones. mRNA expression was 
determined by quantitative real-time PCR and results are normalised to wild-type (wt) cells and expressed as mean ± 
s.e.m. (n=3-5). *p < 0.05, **p < 0.01 ***p < 0.001 vs. wild-type cells. Statistics in (A) were performed after exclusion 
of siscrambled.  
 
Protein Expression of MDR1 and BCRP 
In a next step Western blot analysis was performed to confirm the knock-down on protein level. 
In the Western blot assay, MDR1 protein expression can be detected as a band at a molecular 
weight of 170 kD. As expected in the MDR1-silencing clones (siMDR1 and cosil), no protein 
expression was detectable, while in the wild-type Caco-2 cells, in the negative control 
(siscrambled) and in the BCRP-silencing clone (siBCRP) a clear MDR1 protein expression was 
observed (Figure 8A) 
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It is known from literature (Kage et al., 2002) that BCRP forms homodimers to be functionally 
active. Typically, BCRP protein expression is localised at 72 kD but since we did not heat our 
samples with reducing agents, dimers of BCRP should also be detectable at ~150 kD. In Figure 
8B, the expression of BCRP monomers and dimers is clearly detectable. At 150 kD, BCRP 
dimers are only detected in wild-type cells, in the negative control (siscrambled) and in the 
MDR1-silencing clone. BCRP-dimers are not visible in the BCRP silencing clone (siBCRP) nor 
in the co-silencing clone (cosil). Nevertheless, BCRP monomer expression is seen in all clones at 
more or less the same intensity (Figure 8B) 
 
 
Figure 8 Protein expression of MDR1 (A) and BCRP (B). Beta-actin served as loading control. Protein was extracted 
14 days after seeding and analysis was performed using Western blot technique. 
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Functional Activity of MDR1 and BCRP 
Functional activity of MDR1 and BCRP was assessed by transport and efflux experiments using 
specific substrates. Transport was performed in the direction apical to basolateral with or without 
an inhibitor for the respective protein. Since MDR1 and BCRP are working as efflux transporters 
on the apical side, silencing or inhibition of the transporters should result in an increase in apical 
to basolateral flux. This was clearly shown in the experiments shown in Figure 9. The MDR1 
specific substrate 3H-digoxin showed significant higher transport rates from apical to basolateral 
when MDR1 was inhibited by verapamil. In the case of MDR1-silencing, the transport rate to 
the basolateral compartment is similarly increased as shown in the clones siMDR1 and cosil 
(Figure 9A). 14C-sucrose was used as tightness marker. All clones had a comparable tightness. 
After 2 hours, only 2.5 - 3.25% sucrose was transported from apical to basolateral. The apparent 
permeability coefficient (Papp) for sucrose was determined and was around 1.7 - 2.1*10-9 cm/s. 
14C-PhIP, which is according to literature (van Herwaarden et al., 2003) (Pavek et al., 2005) a 
specific substrate of BCRP, was used in the transport studies for BCRP. When BCRP was 
inhibited with prazosin in wild-type cells, an increase in transport from apical to basolateral was 
observed compared to not-inhibited wild-type Caco-2 cells. A comparable increase in transport 
was also seen in the silencing-clones siBCRP and cosil (Figure 9B). In these transport 
experiments, Lucifer Yellow (LY) was used as tightness marker. The amount of LY transport after 
2 hours was between 2 - 4.5%. Calculations of Papp were about 1.3 – 2.9*10-9 cm/s and 
confirmed, that transport studies were performed across cells forming a tight monolayer. 
The negative control (siscrambled) was also used in these transport experiments and showed 
similar effect on 3H-digoxin and on 14C-PhIP transport compared to Caco-2 wild-type cells. 
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Figure 9 Apical to basolateral transport of 3H-digoxin (66.6 nM, 0.6 µCi/ml) (A) and 14C-PhIP (4 µM, 0.04 
µCi/ml) (B) through Caco-2 monolayers. Verapamil 100 µM and prazosin 50 µM were used as inhibitors of P-gp 
and BCRP, respectively. Data represent means of n=3 ± s.e.m. p < 0.05, **p < 0.01 ***p < 0.001 vs. wild-type cells.  
 
For efflux experiments, cells were pre-loaded with a specific substrate while efflux of MDR1 or 
BCRP was inhibited by verapamil and prazosin, respectively. After preloading, a defined time of 
efflux followed where the substrate was transported out of the cells. The remaining substrate in 
the cells was measured after 1 hour efflux period and compared to cells which were inhibited 
during the efflux period. 
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In MDR1-silencing clones rhodamine 123 (R123) and in BCRP-silencing clones 14C-PhIP were 
used as specific substrates. Figure 10 and Figure 11 show the results of these assays. In wild-type 
cells and in siscrambled-clones R123 remaining substance in the cells differed between inhibited 
and not-inhibited cells (Figure 10A and C). In siMDR1-clones, no difference in these two 
conditions can be seen (Figure 10B). Since in siMDR1-clones MDR1 function is already 
inhibited due to the knock-down, the inhibitor verapamil exhibits no additional effect on the 
function of MDR1. In wild-type cells and in the silencing control, MDR1 is still functionally 
active and can be inhibited by verapamil (Figure 10A and C). 
0 10 20 30 40 50
0
2000
4000
6000
8000
10000
12000
re
m
ai
ni
ng
 fl
uo
re
sc
en
ce
R123 concentration (µM)
 without verapamil
 with verapamil
A
**
**
***
 
0 10 20 30 40 50
0
2000
4000
6000
8000
re
m
ai
ni
ng
 fl
uo
re
sc
en
ce
R123 concentration (µM)
 without verapamil
 with verapamil
B
 
Establishment of the Silencing Method 
53 
0 10 20 30 40 50
0
2000
4000
6000
8000
re
m
ai
ni
ng
 fl
uo
re
sc
en
ce
R123 concentration (µM)
 without verapamil
 with verapamil
C
**
***
***
**
 
Figure 10 MDR1 activity measured using R123 accumulation assay. Cells were loaded with R123 in different 
concentrations and residual accumulation of R123 was measured in the cells after 60 min efflux. Fluorescence was 
measured at 485 nm excitation and 535 nm emission. Remaining substance was compared between not inhibited or 
verapamil (100 µM) -inhibited wild-type (A), siMDR1 (B) and siscrambled (C) Caco-2 cells. A difference is 
indicative for P-gp function. Results are expressed as mean±s.e.m. (n=3). *p < 0.05, **p < 0.01 ***p < 0.001 
 
Residual accumulation of PhIP in the wild-type Caco-2 cells showed a significant difference after 
inhibition with prazosin compared to not-inhibited cells, indicating functional active BCRP 
expression (Figure 11A). Unfortunately, this difference was not significant in the negative control 
siscrambled (Figure 11C). In siBCRP-clones, no difference was observed after inhibition of the 
efflux compared to not-inhibited cells, which indicates the lack of BCRP activity in these 
silencing clones (Figure 11B).  
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Figure 11 BCRP activity measured using PhIP accumulation assay. Cells were loaded with 14C-PhIP in different 
concentrations and residual accumulation was measured in cells after 60 min efflux. Remaining substance was 
compared between not inhibited or prazosin (50 µM) -inhibited wild-type (A), siBCRP (B) and siscrambled (C) 
Caco-2 cells. A difference is indicative to BCRP function. Results are expressed as mean±s.e.m. (n=3). *p < 0.05 
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3.1.5 Discussion 
Silencing is a method which inhibits protein formation by target specific mRNA cleavage. Since 
the availability of completely specific inhibitors of either BCRP or MDR1 is very limited, 
silencing is an appropriate method for selective inhibition of the respective transporter function. 
In the present study we established a vector-based method to permanently knock-down MDR1 
and BCRP in Caco-2 cells. We used pSUPER vector which was developed for stable silencing 
(Brummelkamp et al., 2002). Specific sequences for silencing were designed using established 
algorithms and earlier described sequences were used as positive control, additionally. As negative 
controls, targeting and functional sequences with an inaccurate thermodynamic profile and a 
non-targeting but functional sequence were used. 
Transient transfection revealed good silencing effects of the positive controls and the newly 
designed sequences. With the exception of siMDR1h1, none of our tested sequences exhibited 
any silencing effects on the other investigated gene after transient transfection. The observed off-
target effect of siMDR1h1 on BCRP gene expression was expected since Celius et al. (Celius et 
al., 2004) already observed this effect.  
Unfortunately, the targeting and functional sequences with the inaccurate thermodynamic profile 
(siMDR1h3 and siBCRPh3) which should serve as negative controls also showed silencing effects. 
These sequences were specific for the target gene but had an inaccurate thermodynamic profile. 
Therefore, the RISC should incorporate predominantly the sense strand and no matching to the 
mRNA should occur. Concerning our results, we conclude that the RISC did not selectively enter 
only the sense strand. The antisense strand probably was also included despite the inaccurate 
thermodynamic profile. These data show that it is delicate to design a negative control using 
targeting and functional sequences. Therefore, an additional negative control which was non-
targeting but functional was used. This sequence was earlier described in the literature as 
scrambled silencing control (Taniguchi et al., 2006). As we expected, this sequence had no effects 
on MDR1 and BCRP mRNA expression. 
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Stable silencing Caco-2 clones were selected after 6 passages and the clones with the continuous 
best silencing effects were chosen for further studies. Clones kept their silencing effects for at least 
30 passages and functional assays could be performed with this stable cell lines. 
Silencing of MDR1 was analysed on mRNA, protein and functional level. Silencing of MDR1 in 
Caco-2 cells was already earlier published by (Celius et al., 2004), (Watanabe et al., 2005). They 
achieved a downregulation of MDR1 mRNA expression of 96 and 90%, respectively. We 
approached these results, since our knock-down of MDR1 mRNA was between 75 - 95%. On 
protein level, no MDR1 could be detected by Western blot analysis. The functional activity 
assays confirmed the knock-down of MDR1. 3H-digoxin transport studies in our silencing clones 
showed results similar to verapamil-inhibited wild-type Caco-2 cells, which means a functional 
inhibition of MDR1 activity. R123 efflux assay also endorsed the lack of MDR1-function in the 
siMDR1 clones. 
Stable knock-down of BCRP in Caco-2 cells was not yet reported. Stable BCRP silencing was 
earlier performed in BeWo cells by (Evseenko et al., 2007). They reported a reduction of BCRP 
mRNA expression of about 65%. In our model, we achieved 80 - 90% reduction of BCRP 
mRNA expression, which even exceeded this result. Western blot analysis for the detection of 
BCRP protein expression revealed an interesting finding. Since we did not work under reducing 
conditions, dimers of BCRP should be detectable at ~150 kD in Western blot analysis as 
described previously for Caco-2 cells (Xia et al., 2005). Our protein data show a reduction of 
BCRP dimer expression in the silencing clones compared to controls but the monomer at 72 kD 
varied ambiguously. This fact has to be discussed; a lack of sensitivity in our Western blot analysis 
might be one reason why no difference at 72 kD can be detected. However, further analysis of 
BCRP activity clearly demonstrated a reduction of BCRP function in our clones. We confirmed 
the BCRP-silencing effect measuring BCRP activity in PhIP-transport and –efflux assays. These 
assays all proved a reduced BCRP activity in the BCRP silenced cells. Unfortunately, a slight 
decrease in BCRP mRNA expression was also measured in siMDR1 and siscrambled clones, but 
on protein level BCRP dimer expression still was clearly detectable. However, this fact has to be 
taken into account when analysing BCRP function in siMDR1 and siscrambled clones. 
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Knock-down of both, MDR1 and BCRP, together in a single clone is described for the first time. 
Since both transporters have overlapping substrate specificity, a possible compensation by one 
transporter must be taken into account while the other is inhibited. Relevant interaction of drug 
absorption by MDR1 and BCRP in the intestine can be predicted, while working in Caco-2 cells 
which is a common model for intestinal drug absorption (Artursson et al., 2001). The impact of 
MDR1 and BCRP on the transport of any substrate can be determined in this model and might 
be an interesting tool to predict drug interactions for the in vivo situation. 
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3.2 Transport Studies in Caco-2 Silencing Clones 
 
3.2.1 Abstract 
Background and Purpose: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) 
play a major role in determining the oral absorption of various drugs. Abacavir and Imatinib are 
both transported by P-gp and BCRP. We aimed to identify the influence of P-gp and BCRP on 
drug absorption when one or both transporters are lacking.  
Experimental Approach: Caco-2 wild-type (wt) cells and clones with a stable knock-down of P-
gp, BCRP or P-gp and BCRP (co-silencing) were used. Bidirectional transport and uptake assays 
were performed to measure the influence of each transporter on transport of 3H-abacavir and 14C-
imatinib.  
Key Results: A difference in bidirectional transport means active transport processes while no 
difference stands for passive diffusion. Bidirectional transport with 14C-imatinib revealed a 
significant difference in transport from apical to basolateral (AB) and from basolateral to apical 
(BA) in wild-type cells and BCRP-silencing clones which indicates active transport processes. 
However in P-gp- and in co-silencing clones no difference in bidirectional transport was observed 
which indicates absence of active efflux transport. Residual accumulation after transport was 
significantly higher only in P-gp- and co-silencing clones compared to wild-type. Uptake studies 
with 14C-imatinib only reached significant higher accumulation in the co-silencing clone 
compared to wt. Imatinib as inhibitor of BCRP-function could nullify the difference in transport 
AB and BA of the specific BCRP substrate PhIP in wt cells. Concentration equilibrium transport 
assay with 3H-abacavir resulted in a slight but significant difference in AB and BA transport in wt 
and BCRP-silencing clones, but not in P-gp- and co-silencing clones.  
Conclusions and Implications: Our results with imatinib and abacavir might suggest that P-gp 
plays a more important role than BCRP in intestinal transport of co-substrates. Nevertheless, 
further studies are indicated to verify this observation. Furthermore, possible interferences of our 
cell culture model such as silencing off-target effects have to be ruled out.  
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3.2.2 Introduction 
Gastro-intestinal drug absorption is of major importance since oral drug formulations are widely 
used. Drug solubility and permeability are physicochemical properties that influence drug 
absorption. Lipinski et al. proposed four important properties including logP (octanol:water 
partition coefficient), H-bond-donor and –acceptor and molecular weight, which determine drug 
solubility and permeability (Lipinski et al., 2001). In the last years, intestinal metabolism and 
active efflux transport in the intestine have been recognised as major determinants of drug 
bioavailability (Benet et al., 1996). Active efflux into the intestinal lumen or metabolism in the 
intestinal cells can drastically lower bioavailability of drugs. Active efflux is mainly mediated by 
the ATP-binding-cassette-transporters family. Among these transporters, P-glycoprotein (P-gp) 
and breast cancer resistance protein (BCRP) play an important role. Their expression is high at 
excretory sites amongst other tissues also in the intestine. They are expressed at the apical brush 
border membrane of the intestine and form a barrier for various drugs and toxins (Cordon-Cardo 
et al., 1990), (Thiebaut et al., 1987), (Maliepaard et al., 2001). Both transporters have broad and 
partly overlapping substrate specificity. Interaction of drugs at the level of efflux-transport can be 
the consequence.  
Imatinib and abacavir belong to newly discovered substrates of both, P-gp and BCRP. Imatinib is 
an anti-proliferative drug and is primarily used in Philadelphia chromosome positive chronic 
myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) or gastrointestinal 
stromal tumours. It belongs to the family of tyrosine-kinase inhibitors and inhibits selectively the 
BCR-ABL fusion protein, the tyrosinkinase-receptor c-KIT and the platelet-derived growth factor 
receptors (Buchdunger et al., 2000), (Druker et al., 2001), (van Oosterom et al., 2001). Imatinib 
is orally taken and its bioavailability is about 98% (Peng et al., 2004). Bioavailability of imatinib 
is high but varying plasma AUC (area under the curve) are described, possibly due to metabolism 
and transport processes (Peng et al., 2005). Recently, it was described that imatinib is a substrate 
of human P-gp and BCRP (Hamada et al., 2003), (Burger et al., 2004). 
Abacavir is an anti-retroviral drug and belongs to the class of nucleoside reverse transcriptase 
inhibitors (NRTI). It is used in the therapy of HIV infections in combination with other NRTIs, 
non-NRTIs and protease inhibitors (Josephson et al., 2007). The oral bioavailability of abacavir is 
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about 83% (Chittick et al., 1999). Two recently published studies showed that abacavir is a 
substrate of human P-gp and murine Bcrp1 (Shaik et al., 2007), (Pan et al., 2007).  
Interactions of these two substrates in an intestinal model are not yet published. A suitable in 
vitro model for intestinal transport processes are Caco-2 cells (Hidalgo et al., 1989). It was shown 
that the expression of ABC-transporters in Caco-2 cells have in general a good correlation to the 
expression level in the human intestine (Taipalensuu et al., 2001).  
The aim of this study was to investigate how co-substrates of P-gp and BCRP are transported in 
the situation where one or both of these transporters are inhibited.  
 
3.2.3 Methods 
Materials  
14C-Imatinib mesylate (52.74 mCi/mmol) was kindly gifted by Novartis Pharma AG (Basel, 
CH). 14C-PhIP (10 mCi/mmol) was from Toronto Research Chemicals Inc. (Toronto, Ontario, 
Canada). Abacavir and 3H-abacavir (0.5 Ci/mmol) was purchased from Moravek Biochemicals, 
(Brea, CA, USA). 14C-sucrose (588 mCi/mmol) was from Perkin Elmer (Schwerzenbach, CH) 
Lucifer Yellow (LY) (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in phosphate buffered 
saline (PBS) (Invitrogen, Basel, CH). Prazosin (Sigma-Aldrich) was dissolved in DMSO. 
Elacridar was kindly gifted from Roche (Basel, CH) and dissolved in DMSO. 
 
mRNA Expression of MDR1 and BCRP: see chapter 2.2 
Sequences for primers and probes are listed in Table 1. 
Protein Expression of MDR1 and BCRP: see chapter 2.3 
Bidirectional Transport of Imatinib and Abacavir 
Transport assay was performed as described in chapter 2.4. The assay with14C-imatinib was 
performed with Caco-2 cells grown on polycarbonate filters, while for 3H-abacavir and for 14C-
PhIP polyester filters were used. For bidirectional transport assays, samples were taken after, 20, 
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40, 60, 90 and 120 min. Lucifer Yellow (20 µM) was used as tightness-marker in the 14C-
imatinib and 14C-PhIP assays and 14C-sucrose (0.6 µCi/ml) was used in the assay with 3H-
abacavir. 
Concentration equilibrium transport assay was performed for abacavir transport. On both sides 
the same concentration of the substrate was added and the tightness-marker was added only at the 
apical side. At every time point samples were taken on the apical and basolateral side. Removed 
volume was not replaced after sampling in order not to change the developing concentration 
gradient. Therefore only small sample sizes of the same proportion were taken on both sides. 
 
3.2.4 Results 
Validation of Cell System 
Validation of Caco-2 silencing is described in detail in chapter 1.1. 
 
Imatinib 
Imatinib is a substrate of P-gp and BCRP. Using 14C-imatinib in Caco-2 cells we investigated 
whether these two transporters can compensate imatinib-efflux when one or both of these 
transporters are downregulated.  
An uptake assay was performed for one hour using elacridar (10 µM) as inhibitor of both 
transporters. An increase of 14C-imatinib as remaining substance in the cells indicates less efflux 
processes and consequently lower activity of P-gp and BCRP. In Figure 12, remaining 14C-
imatinib in not inhibited cells normalised to elacridar-inhibited cells are shown. In the P-gp-
silencing clone (siMDR1) and in the co-silencing clone (cosil) more 14C-imatinib accumulates in 
the cells compared to wild-type Caco-2, but significance is only reached in the cosil-clone. In the 
BCRP-silencing clone (siBCRP) no alteration is observed compared to wild-type cells. These 
results show that accumulation of 14C-imatinib tends to increase when P-gp activity is decreased 
but not when only BCRP is downregulated. 
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Figure 12 Accumulation of 14C-imatinib (10 µM, 0.02 uCi/ml) in Caco-2 cells after 1 hour uptake. Data represent 
14C-imatinib normalised to elacridar (10 µM)-treated cells. An increase in 14C-imatinib is indicative for decreased 
efflux function. Results are expressed as mean±s.e.m. (n=3). *p<0.05 
 
Transport assays were performed to study bidirectional transport of 14C-imatinib through a 
monolayer. Transport in both directions from apical to basolateral (AB) and from basolateral to 
apical (BA) was measured. More transport BA means active efflux on the apical membrane. In 
Figure 13 we can see that Caco-2 wild-type cells have an asymmetry in transport direction. More 
14C-imatinib is transported to the apical compartment which stands for active efflux function on 
the apical side. This asymmetry is reversed in P-gp- and co-silencing clones (siMDR1 and cosil). 
In BCRP-silencing clone (siBCRP) the asymmetry of transport is still present. Therefore, efflux 
activity at the apical side is still present in BCRP-silencing clones, but in P-gp- and co-silencing 
clones, no active efflux can be seen.  
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Figure 13 Bidirectional transport of 14C-imatinib (11,4 µM, 0.6 µCi/ml) in Caco-2 wild-type cells and silencing 
clones. Percentage of transport apical to basolateral (AB) and basolateral to apical (BA) is plotted against time. Data 
represent mean±s.e.m. (n=3). *p<0.05, **p<0.01, ***p<0.001 
 
Measurement of remaining 14C-imatinib in wild-type, MDR1-, BCRP- and co-silencing clones 
revealed a comparable result (Figure 14). Higher levels of 14C-imatinib are indicative for reduced 
efflux function. In clones where P-gp activity was abolished by the knock-down, significantly 
more imatinib accumulates in the cells. In the clone where only BCRP is silenced, the 
accumulation in the cells is not significantly increased. 
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Figure 14 Remaining 14C-imatinib (11.4 µM, 0.6 µCi/ml) in wild-type Caco-2 and silencing clones after 2 hours 
transport. Data represent means±s.e.m. (n=3). *p<0.05 
 
In a control experiment, we tested 14C-PhIP-transport across wild-type Caco-2 cells and Caco-2 
wild-type cells inhibited with imatinib and in BCRP-silencing clone (Figure 15). Transport of 
PhIP across Caco-2 wild-type cells shows a wide asymmetry while in cells, which are inhibited 
with imatinib, this asymmetry decreases which indicates inhibition of BCRP efflux activity at the 
apical side. In the BCRP-silencing clone this asymmetry is also reversed indicating loss of efflux 
transport. 
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Figure 15 Bidirectional Transport of 14C-PhIP (4 µM, 0.04 µCi/ml) across Caco-2 wild-type cells without inhibitor, 
with prazosin (50 µM) and imatinib (100 µM) as inhibitors and in BCRP-silencing clone (siBCRP). Percentage of 
transport apical to basolateral (AB) and basolateral to apical (BA) is plotted against time. Data represent mean±s.e.m 
(n=3). *p<0.05, **p<0.01, ***p<0.001 
 
 
Abacavir 
Abacavir was described as substrate of P-gp and Bcrp. We evaluated its transport by P-gp and 
BCRP in the intestinal cell model Caco-2. Abacavir showed good permeability over the cell 
monolayer and discrimination between the different clones was not possible. Therefore we 
worked with a concentration-equilibrium where on both sides of the membrane the same 
concentration of drug was applied. Using this system, passive diffusion in the direction of the 
concentration gradient is reduced. In Figure 16, concentration of 3H-abacavir in the respective 
compartment is shown at the indicated time-points. A difference in drug concentration between 
the compartments means active transport. Differences of concentration in each compartment are 
minimal but there still can be seen some effects. A significant difference is observed in Caco-2 
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wild-type cells, where both tranporters P-gp and BCRP are active. No significant difference is 
seen in the co-silencing clone (cosil). A reduced difference is also seen in the P-gp-silencing clone 
(siMDR1), but in the BCRP-silencing clone (siBCRP) concentration in both compartments is 
clearly differing.  
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Figure 16 Concentration-equilibrium transport assay. Concentration of 3H-abacavir (80 nM, 0.04 µCi/ml) in both 
compartments are shown for the different clones (wt, siMDR1, siBCRP, cosil). Data represent mean±s.e.m. (n=3). 
*p<0.05, **p<0.01 
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3.2.5 Discussion 
In this study we investigated imatinib and abacavir transport through monolayers of Caco-2 cells. 
Caco-2 cells were shown to represent an ideal in vitro model for intestinal transport processes 
(Hidalgo et al., 1989). We established a model of single and concomitant knock-down of P-gp 
and BCRP. Using this model, we tested interactions of these substrates with the transporters 
when one or both are silenced. 
Imatinib is an orally applied anti-cancer drug, which can evoke therapy resistance after long-term 
treatment. A possible explanation for therapy resistance is the overexpression of active efflux-
transporters. The role of ABC-transporters in therapy resistance is discussed. Several studies 
showed that imatinib is a substrate of P-gp (Hamada et al., 2003), (Dai et al., 2003), (Mahon et 
al., 2003). Studies in Caco-2 cells showed that imatinib induced P-gp and BCRP expression 
which lead to reduced intracellular drug accumulation (Burger et al., 2005). We could confirm 
that P-gp plays a certain role in transport of imatinib in the intestinal model Caco-2. When P-gp 
is silenced, only around half of the amount of imatinib is transported to the apical compartment 
(Figure 13) and almost twice as much remains in the cells compared to wild-type Caco-2 cells 
(Figure 14).  
Furthermore, we silenced BCRP in Caco-2 cells. Interactions between imatinib and BCRP are 
intensively discussed in literature. Several authors demonstrated that imatinib is a substrate of 
BCRP while others concluded that it is only an inhibitor of BCRP. Jordanides et al. (Jordanides 
et al., 2006) and Houghton et al. (Houghton et al., 2004) both showed that imatinib is an 
inhibitor of BCRP function, but is not transported by BCRP. In contrast to these results several 
authors revealed that imatinib is not only an inhibitor, but also a substrate of BCRP (Burger et 
al., 2004), (Breedveld et al., 2005). Shukla et al. demonstrated that imatinib interacts at the 
transport-substrate binding sites of BCRP and P-gp (Shukla et al., 2007). Furthermore, 
Nakanishi et al. showed that imatinib-induced cytotoxicity in BCRP-transfected cell lines is lower 
than in not-transfected cell lines. (Nakanishi et al., 2006).  
Our results confirm the fact that imatinib is an inhibitor of BCRP function, since it inhibited the 
transport of the specific BCRP-substrate PhIP (Figure 15). Transport studies of 14C-imatinib in 
our cell model show interesting findings. In Caco-2 cells where only BCRP is silenced, there is no 
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difference in 14C-imatinib transport compared to wild-type cells. Remaining imatinib in cells after 
two hours transport shows a slight but not significant increase in BCRP-silenced clones. An 
explanation for this observation might be P-gp-function. In the BCRP-silencing clone P-gp still is 
highly expressed and possibly compensates the loss of BCRP-function. However, on the other 
hand, in P-gp-silencing clones, we cannot see a compensation of BCRP-transport when P-gp 
activity is lacking. But in the co-silencing clone, where both, P-gp and BCRP, are silenced, 
remaining 14C-imatinib after two hours transport is higher compared to the single P-gp-silencing 
clone. This result might indicate that P-gp and BCRP both transport imatinib but P-gp possibly 
plays a more important role. These conclusions are in accordance with results of Bihorel et al. 
(Bihorel et al., 2007a), (Bihorel et al., 2007b). In a mouse model, knock-out of mdr1a/1b (-/-) 
increased the brain-to-blood ratio but knock-out of bcrp1(-/-) showed the same ratio compared 
to wild-type mice. However, inhibition of P-gp and BCRP in wild-type mice with elacridar 
increased the brain-to-blood ratio compared to single inhibition of P-gp with valspodar or 
zosuquidar.  
The second investigated substrate in our cell system was the nucleoside reverse transcriptase 
inhibitor (NRTI) abacavir. Among anti-HIV drugs interactions at transporters-side are well 
known. Many anti-HIV drugs have inhibitory potencies on P-gp and BCRP (Weiss et al., 2007), 
(Storch et al., 2007). In these studies, abacavir was described to be a very weak inhibitor of P-gp 
and BCRP. In addition, recent investigations revealed that abacavir is a substrate of human P-gp 
and mouse Bcrp1 (Shaik et al., 2007), (Pan et al., 2007). In our Caco-2 system transport of 
abacavir by P-gp and BCRP was determined. Transport of abacavir from apical to basolateral was 
extensive and interactions between the different silencing clones were hardly detectable (data not 
shown). Therefore, a concentration-equilibrium transport assay was performed in order to 
minimise the effect of passive diffusion. Considering results of abacavir transport, effects of P-gp 
and BCRP on abacavir absorption are small but detectable. When both transporters are silenced, 
almost the same concentrations on both sides of the membrane were detected, while in wild-type 
cells more abacavir was measured in the apical compartment probably due to active efflux. 
Silencing of P-gp reduced this apical-to-basolateral transport more clearly than silencing of 
BCRP. Reasons for this observation again might be compensation of transport by P-gp when 
BCRP is silenced. On the other hand, since single P-gp-silencing is not as effective as co-silencing 
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of both transporters, BCRP still is active but probably is not able to compensate the loss of P-gp 
function. 
Summarising our findings with imatinib and abacavir, we could see that single silencing of P-gp 
had more potent effects on transport of these two substrates than single silencing of BCRP. 
Possible explanations could be a stronger affinity of these substrates to P-gp than to BCRP. 
Interestingly, both substrates showed a similar tendency. A further explanation to this fact also 
could be due to our system. On mRNA level we observed a slight downregulation of BCRP in P-
gp-silencing clones (chapter 3.1.4). However, this downregulation is very low but further 
experiments have to be performed to verify a full functionally active BCRP in P-gp-silencing 
clones.  
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4 Regulation of ABC-Transporters 
 
4.1 Effects of Budesonide on P-glycoprotein Expression in Intestinal Cell 
Lines 
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4.1.1 Abstract 
Background and Purpose: P-glycoprotein (P-gp) is an important efflux transporter that supports 
the barrier function of the gut against invading antigens and against administered drugs. Since 
glucocorticoids, such as budesonide, are frequently used during inflammatory bowel disease we 
investigated how budesonide influences P-gp expression in different intestinal cell lines. 
Experimental Approach: LS180 and Caco-2 cells were incubated with budesonide and changes in 
P-gp expression were determined on mRNA, protein and functional level. The mRNA expression 
levels of glucocorticoid receptor (GR) and pregnane X receptor (PXR) were determined in the 
investigated cell lines. PXR receptor was transiently transfected into Caco-2 cells.  
Key Results: Budesonide showed an induction of P-gp in LS180 cells and a downregulation in 
Caco-2 cells. Expression levels of nuclear receptors revealed high expression of PXR only in 
LS180 cells and exclusive expression of GR in Caco-2 cells. Mifepristone, an antiglucocorticoid, 
could not reverse the downregulation of P-gp by budesonide in Caco-2 cells. In PXR-transfected 
Caco-2 cells the budesonide-mediated downregulation of P-gp was abolished. Furthermore the 
expression of cytochrome P450 3A4 (CYP3A4), another PXR target gene, was induced in PXR-
transfected Caco-2 cells after budesonide treatment.  
Conclusions and Implications: Budesonide has the potential to influence MDR1 expression in 
vitro. In LS180 cells, the induction of MDR1 by budesonide probably is mediated via PXR. The 
mechanism of the downregulation in Caco-2 cells still remains unclear, but GR does not seem to 
be involved. Further studies are required to evaluate how budesonide alters P-gp expression in 
vivo.  
 
Budesonide and P-glycoprotein Regulation 
72 
4.1.2 Introduction 
Glucocorticoids are an important therapeutic option in treating inflammatory disorders like 
asthma, rheumatoid arthritis or inflammatory bowel disease (IBD). Budesonide is a newer 
synthetic glucocorticoid that is increasingly used in IBD patients (Kane et al., 2002). If applied in 
a controlled release formulation, budesonide is after oral administration topically released in the 
distal small intestine and colon, the predominant sites of inflammation (Klotz and Schwab, 
2005). There, it is well absorbed, but it is extensively pre-systemically metabolized (Schwab and 
Klotz, 2001). Consequently, upon oral administration budesonide exerts strong anti-
inflammatory effects in intestinal tissue with minimal systemic side effects (Hofer, 2003).  
The molecular mechanism of glucocorticoid action involves the intracellular binding to the 
glucocorticoid receptor (GR), followed by a translocation of activated GR to the nucleus. There, 
it stimulates or inhibits gene expression by binding to glucocorticoid response elements on DNA 
(Wright et al., 1993). Moreover, ligand-bound GR can repress a number of pro-inflammatory 
genes by physically associating with transcription factors via direct protein-protein interactions. 
Examples are the repression of nuclear factor-κB (NF-κB) or activator protein-1 (AP-1) (Smoak 
and Cidlowski, 2004). 
Glucocorticoids such as dexamethasone are further known to activate the pregnane X receptor 
(PXR) (Kliewer et al., 1998). PXR belongs to the group of orphan nuclear receptors that function 
as heterodimers with the retinoic X receptor (RXR) (Chawla et al., 2001). They are important 
regulators of xenobiotic metabolism and upon activation they can induce the expression of 
metabolizing enzymes (e.g. cytochrome P450 3A4) and drug transporters such as P-glycoprotein 
(P-gp) (Bertilsson et al., 1998), (Geick et al., 2001).  
P-gp is the gene product of the multi-drug resistance gene 1 (MDR1, gene symbol: ABCB1). It is 
an adenosine-triphosphate-dependent drug efflux pump with wide substrate specificity (Juliano 
and Ling, 1976). It has barrier function in tissues such as kidney, blood brain barrier and 
intestine (Cordon-Cardo et al., 1990). In the intestine, P-gp is localized in the apical membrane 
of epithelial cells and is continuously expressed along the intestinal tract (Thiebaut et al., 1987), 
(Zimmermann et al., 2005). Therefore, P-gp can significantly influence the bioavailability of 
many drugs including glucocorticoids, as it has been shown previously that budesonide, 
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dexamethasone, and prednisone are substrates of this transporter (Dilger et al., 2004), (Fromm, 
2003), (Ueda et al., 1992). Besides the induction through PXR, the expression level of MDR1 is 
dependent on a complex transcriptional regulation with a redundancy of signalling pathways 
(Labialle et al., 2002).  
Several publications demonstrated that dexamethasone induces MDR1 expression in the intestine 
of rats (Lin et al., 1999), (Perloff et al., 2004), (Yumoto et al., 2001). So far, there is no 
explanation how glucocorticoids, in particular budesonide, influence MDR1 expression in human 
intestinal cells. Here, we investigated how the glucocorticoid budesonide influences the 
expression of MDR1 in different human intestinal cell lines. We chose Caco-2 cell line, as it 
shows transporter expressions comparable to those in the human jejunum (Taipalensuu et al., 
2001). Furthermore, these cells are an established model for small intestinal transport. (Hidalgo et 
al., 1989). Secondly, we used LS180 cells, which are a suitable model for intestinal gene 
induction studies (Bhat et al., 1995), (Thummel et al., 2001), (Zhou et al., 2004). Their 
expression level of efflux transporters is similar to human colonic tissue (Pfrunder et al., 2003). 
The findings of this study could be relevant in evaluating the involvement of P-gp in 
glucocorticoid action and glucocorticoid side effects.  
 
4.1.3 Methods 
Chemicals  
Budesonide (Sigma-Aldrich, St. Louis, MO, USA), rifampicin (Fluka Chemie, Buchs SG, 
Switzerland), and actinomycin D (Sigma-Aldrich) were dissolved in dimethylsulfoxide (DMSO). 
Mifepristone (Sigma-Aldrich) and rhodamine 123 (Molecular Probes, Eugene, OR, USA) were 
dissolved in ethanol.  
 
Cell Culture  
The LS180 (used between passage 40 and 50) and Caco-2 cell line (used between passage 54 and 
70) were purchased from ATCC (Manassas, USA). LS180 and Caco-2 cells were cultured in 
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Dulbecco’s MEM with Glutamax-I, supplemented with 10% (v v-1) fetal bovine serum, 1% non 
essential amino acids, 1% sodium pyruvate, 50 µg mL-1 gentamycin (Invitrogen AG, Basel, 
Switzerland). Cells were seeded into 12 well plastic culture dishes (3.8 cm2 per well, BD Falcon 
AG, Allschwil, Switzerland) and were maintained in a humidified 37°C incubator with a 5% 
carbon dioxide in air atmosphere. After Caco-2 cells had reached confluence or nearly confluence 
for LS180, they were treated with the substances as indicated or with vehicle alone. Medium was 
changed every 24 hours. Toxicity was tested in advance for all applied substances using 
sulforhodamine B staining (Sigma-Aldrich) (Skehan et al., 1990). 
 
Real-time RT-PCR: see chapter 2.2 
Sequences for primers and probes are described in Table 1. Sequences for GR alpha and GR beta 
were adopted from a previous paper (Pedersen et al., 2003).  
 
Western Blot Analysis  
LS180 and Caco-2 cells were incubated for 72 hours with 25 µM budesonide or with vehicle 
(0.25% DMSO) as a negative control. LS180 cells additionally were incubated with 10 µM 
rifampicin.  
For protein extraction and western blot see chapter 2.3.  
 
Rhodamine 123 Accumulation Assay  
LS180 and Caco-2 cells were incubated for 72 hours either with medium containing 20 µM 
budesonide or vehicle only (0.2% DMSO). LS180 cells were additionally incubated with 10 µM 
rifampicin. Medium was changed every day. Following drug treatment, efflux assay with 
rhodamine 123 (R123) was performed as described in chapter 2.6.  
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R123 fluorescence was analysed with a HTS 7000 Plus Bio Assay Reader (Perkin Elmer Ltd., 
Buckinghamshire, UK) with 485 nm excitation and 535 nm emission filters. The ratio of 
intracellular R123 fluorescence in the absence and presence of verapamil is indicative of the 
activity of P-gp. This approach has previously been reported for the measurement of P-gp activity 
in LS180 cells (Collett et al., 2004). 
 
mRNA Decay Measurement  
The measurement of mRNA stability was performed in Caco-2 cells using actinomycin D as an 
inhibitor of transcription. Cells were preincubated for 1 hour with budesonide 25 µM or vehicle. 
Actinomycin D (5 µg mL-1) was added and total RNA was extracted after different time points. 
The expression level of MDR1 mRNA after 0, 4, 8, 24 and 48 hours was determined by real-time 
reverse transcription (RT-)PCR.  
 
Transfections  
The Full ORF Expression vectors of PXR (IOH34726-pT-Rex-DEST30) was purchased from 
the Deutsches Ressourcenzentrum für Genomforschung GmbH. The empty vector was obtained 
by cutting the PXR plasmid with the restriction enzymes EcoRV and Mlu I followed by 
purification on a 0.5% agarose gel. The cut ends were blunt-ended with T4 DNA polymerase 
and self-circulated with T4 DNA ligase. Transfection was performed with Lipofectamine 2000 
(Invitrogen) during 48 hours following the manufacturer’s protocol using 1.6 µg DNA and 4 µL 
Lipofectamine 2000. As negative control the empty vector was used. After transfection Caco-2 
cell were incubated with budesonide 25 µM and rifampicin 10 µM or vehicle only. Transfection 
was verified by measuring PXR mRNA expression using TaqMan analysis.  
 
Statistics 
Treatment groups were compared to control group by analysis of variance (ANOVA). If this 
analysis revealed significant differences and more than one treatment group was included in the 
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analysis, pairwise comparisons of treatment groups with the control group was performed 
subsequently using Dunnett’s two-sided multi-comparison test or multiple unpaired two-sided t-
test with Bonferoni’s correction, as appropriate, to account for the multiplicity of testing. All tests 
were performed using the SPSS for Windows software (version 14.0). The level of significance 
was P<0.05.  
 
4.1.4 Results 
MDR1 mRNA Expression  
The basal MDR1 mRNA expression level was higher in Caco-2 cells compared to LS180 cells. 
The effect of budesonide on MDR1 mRNA expression was investigated in these two different 
intestinal cell lines (LS180 and Caco-2). Cells were incubated for 48 hours with increasing 
budesonide concentrations and mRNA expression was analysed using real-time RT-PCR. In 
LS180 cells, we observed a dose-dependent induction of MDR1 mRNA expression by 
budesonide (Figure 17A). Rifampicin as a positive control also showed an induction. In Caco-2 
cells, MDR1 mRNA expression decreased in a dose-dependent manner after budesonide 
treatment (Figure 17B). 
 
Figure 17: Effect of budesonide on MDR1 mRNA expression in LS180 (A) and Caco2 (B) cell lines. Cells were 
incubated for 48 hours and mRNA expression was determined by quantitative real-time PCR. Rifampicin was used 
as a positive control for MDR1 induction in LS180 cells. Results are normalized to control cells and expressed as 
mean ± s.e.m. (n=4). *p < 0.05, ***p < 0.001 vs. control cells.  
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MDR1 Protein Expression  
The observed changes in MDR1 mRNA expression in LS180 and Caco-2 cells were confirmed 
on protein level by Western blot analysis (Figure 18). In three independent assays cells were 
incubated for 72 hours with 25 µM budesonide and 10 µM rifampicin. Compared to control 
cells, MDR1 protein levels increased in LS180 cells and decreased in Caco-2 cells after 
budesonide treatment.  
 
Figure 18 Effect of budesonide on P-gp protein expression. LS180 and Caco-2 cells were incubated for 72 hours with 
25 µM budesonide or vehicle. Rifampicin was used as a positive control for MDR1 induction in LS180 cells. P-gp 
protein and beta-actin were determined by Western blot analysis. Beta-actin was used as loading control. 
 
Measurement of P-gp Activity  
R123 is a fluorescent P-gp substrate that can be used for the determination of P-gp activity 
(Figure 19). After passive diffusion into the cells it is actively transported out of the cell by P-gp. 
Measurement of cellular R123 accumulation revealed that the observed changes of MDR1 
expression are reflected by changes in P-gp function. In LS180 cells, where MDR1 is induced by 
budesonide, relative R123 uptake was significantly lower compared to control cells. Similar 
effects were observed for rifampicin, a positive control for MDR1 induction in LS180 cells. In 
Caco-2 cells, the decreased MDR1 expression led to a significant accumulation of intracellular 
R123.  
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Figure 19 P-gp activity was assessed using Rhodamine 123 accumulation in LS180 and Caco-2 cells. Cells were pre-
treated with 20 µM budesonide or vehicle for 72 hours. Rifampicin was used as a positive control for P-gp induction. 
Data represent Rhodamine 123 fluorescence normalized to verapamil treated cells. A decrease in intracellular 
fluorescence is indicative of an increase in P-gp activity and vice versa. Results are expressed as mean ± s.e.m. (n=3-4). 
**p < 0.01, ***p < 0.001 vs. control cells. 
 
Expression of the Nuclear Receptors PXR and GR in Intestinal Cell Lines 
To elucidate the differential effects of budesonide on the expression of MDR1 in the cell lines 
studied, we determined whether this could be attributed to differential expression levels of 
nuclear receptors (Figure 20). Glucocorticoids exert their anti-inflammatory effects through the 
GR-α. However, the PXR can also be activated by glucocorticoids like dexamethasone. Real-time 
PCR analysis (n=4 for both cell lines) revealed low expression levels of PXR in Caco-2 cells and 
high expression in LS180 cells. GR alpha, on the other hand, was exclusively expressed in Caco-2 
cells. As the GR beta apparently exhibits inhibitory effects on the GR alpha, we analysed also the 
expression rate of this receptor. However, no GR-β mRNA was detectable in both cell lines. 
There was no effect of budesonide treatment on these receptors. In addition, basal MDR1 
mRNA expression was not correlated to PXR expression level in both investigated cell lines.  
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Figure 20 Expression of PXR and GR alpha mRNA in the investigated intestinal cell lines Caco-2 and LS180. 
Expression was determined by quantitative real-time PCR. Results are expressed as mean ± s.e.m. (n=4). ND = not 
detectable. 
 
Effect of Mifepristone on MDR1 mRNA Expression in Caco-2 Cells  
To determine whether the GR plays a role in the budesonide-induced downregulation of MDR1 
in Caco-2 cells, mifepristone (RU486) a known anti-glucocorticoid was used. Mifepristone could 
not reverse the effect of budesonide when co-applied; when the drug was given alone, it induced a 
similar downregulation of MDR1 (Figure 21).  
 
Figure 21 Effect of the anti-glucocorticoid mifepristone on MDR1 mRNA expression. Cells were incubated for 48 
hours and mRNA expression was determined by quantitative real-time PCR. Results are normalized to control cells 
and expressed as mean ± s.e.m. (n=4). ***p < 0.001 vs. control cells. 
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MDR1 mRNA Stability  
We have shown that budesonide decreases the expression of MDR1 in Caco-2 cells on the 
mRNA level. However, beside a transcriptional regulation, this result could also reflect a decrease 
in mRNA stability. Therefore, we determined the decay of MDR1 mRNA after the addition of 
the transcription inhibitor actinomycin D in Caco-2 cells (Figure 22). The stability of MDR1 
mRNA was not different between control cells and cells treated with budesonide. For both 
treatments the half-life of MDR1 mRNA in Caco-2 cells appeared to be about 20 h.  
 
Figure 22 Effect of budesonide on MDR1 mRNA stability in Caco-2 cells. Cells were treated with 25 µM 
budesonide or vehicle while transcription was inhibited with actinomycin D (5 µg ml-1). mRNA expression was 
determined by quantitative real-time PCR after 0, 4, 8, 24 and 48 h incubation. Each data value is expressed relative 
to the expression at 0 hours. Data represent mean ± s.e.m. (n=3). 
 
 
Transfection of PXR into Caco-2 Cells  
To investigate whether PXR is involved in the regulation of MDR1 by budesonide, PXR was 
transiently transfected into Caco-2 cells. Caco-2 cells express only low levels of endogenous PXR 
and known PXR activators such as rifampicin are not able to induce PXR target genes in Caco-2 
cells (data not shown and (Pfrunder et al., 2003)). In a control experiment, cells transfected with 
the empty vector showed the expected downregulation of MDR1 mRNA after budesonide 
treatment and no changes after rifampicin treatment compared to control cells. On the other 
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hand, PXR transfection could reverse the downregulation of MDR1 mRNA after budesonide 
treatment. Rifampicin, the positive control for PXR activation, induced MDR1 mRNA in PXR-
transfected Caco-2 cells (Figure 23A).   
CYP3A4, another target gene of PXR, is only slightly expressed in Caco-2 cells. Nevertheless, in 
parallel to MDR1, we could see a significant induction of CYP3A4 in PXR-transfected Caco-2 
cells after treatment with budesonide and rifampicin (Figure 23B).  
 
Figure 23 Expression of MDR1 (A) and CYP3A4 (B) in Caco-2 cells transfected with the empty vector (-pPXR) and 
PXR vector (+pPXR) after treatment with budesonide, rifampicin or vehicle only. In two independent experiments, 
cells were transfected during 48 hours, followed by 48 hours drug-treatment. mRNA expression was determined by 
quantitative real-time PCR. Results are normalized to the respective control cells and expressed as mean ± s.e.m. 
(n=5-6). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control cells.  
 
4.1.5 Discussion 
At present, there are no data about the intestinal regulation of MDR1 by budesonide. Given that 
this glucocorticoid is often used in the treatment of IBD, we investigated its effects on MDR1 
expression in two different, frequently used intestinal cell lines. Our results indicate that the 
regulation of this efflux transporter by budesonide is complex. MDR1 expression was induced in 
LS180 cells; in contrast, it was downregulated in Caco-2 cells. 
 An altered intestinal expression of P-gp can have important clinical implications. On the one 
hand, an induction of MDR1 can lead to an increased efflux of P-gp substrates out of the 
enterocytes (Westphal et al., 2000). Ineffective therapy or even therapy resistance could be the 
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outcome. On the other hand, a decreased expression can impair the barrier function of the 
intestinal epithelial cells. In this respect, it was shown that mice deficient for mdr1a developed an 
inflammation of the large intestine similar to IBD (Panwala et al., 1998). The inflammation was 
dependent on the presence of intestinal bacteria, suggesting a function of P-gp to protect the 
body from toxins produced by intestinal bacteria. This hypothesis is in concordance with data 
from patients with ulcerative colitis, where the expression of MDR1 and PXR was significantly 
reduced in mucosal biopsy specimens from non-affected regions of the colon and terminal ileum 
(Langmann et al., 2004). Here, we have shown that in Caco-2 cells MDR1 expression was 
repressed by budesonide in a dose-dependent manner. An enhanced mRNA decay is not 
responsible for the observed MDR1 downregulation (as shown in the experiments with 
actinomycin D), although increased MDR1 mRNA decay with dexamethasone has been reported 
in primary rat hepatocytes (Schuetz et al., 1995). 
In contrast to LS180 cells, the GR was highly expressed in Caco-2 cells. This led us to assume 
that the GR could mediate the observed downregulation of MDR1 in this cell line. The 
downregulation by budesonide occurred, however, in the range of micromolar concentrations 
only, despite the fact that the GR receptor has a high affinity for glucocorticoids. Furthermore, 
the addition of mifepristone (RU486), an established antagonist at the GR, did not abolish this 
effect. In fact, mifepristone repressed MDR1 expression in the same way as budesonide. 
Therefore, the involvement of the GR can most likely be ruled out, but the mechanism behind 
the repression of MDR1 in Caco-2 cells remains still unclear. However, a not yet identified 
unspecific effect appears to be most likely.  
In contrast, when we used LS180 cells as an intestinal model, incubations with budesonide 
showed an increase in MDR1 expression. We assumed that budesonide might be able to activate 
PXR, leading to an induction of MDR1 and other PXR target genes.  
An unspecific induction of MDR1 through toxic drug effects could be ruled out by performing 
cytotoxicity assays prior to the incubation procedures. In our experiments, the induction occurred 
with budesonide concentrations starting from 10 µM. This is in concordance with the fact that 
PXR is a receptor with only low affinity for glucocorticoids, since the affinity of corticosterone for 
PXR was reported to be in the range of 10 - 30 µM (Sheppard, 2002). The applied budesonide 
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concentrations up to 25 µM are high, but they could represent relevant local concentrations in 
the gut lumen after oral administration or when the drug is applied rectally as an enema. The 
induction of MDR1 in the intestine through glucocorticoids has been shown previously for 
dexamethasone in the rat (Lin et al., 1999), (Perloff et al., 2004), (Yumoto et al., 2001). The 
mechanism of this upregulation by glucocorticoids seems to involve PXR. Pascussi et al. 
demonstrated that dexamethasone activates the nuclear receptor PXR (Pascussi et al., 2001). 
Furthermore it has been shown that PXR mediates MDR1 induction (Geick et al., 2001). 
From our experiments, there are several lines of evidence to support the suggestion that 
budesonide induces MDR1 expression through activation of PXR. Firstly, PXR expression was 
high in LS180 cells, where we observed an induction of MDR1. Secondly, rifampicin, a known 
activator of PXR (Geick et al., 2001), induced MDR1 in parallel with budesonide in LS180 cells. 
Finally, the PXR target genes MDR1 and CYP3A4 were induced in PXR-transfected Caco-2 cells 
compared to cells transfected with the empty vector.  
In PXR-transfected Caco-2 cells, the induction of MDR1 apparently resulted in a reversal of the 
previously observed downregulation. For CYP3A4, on the other hand, a clear induction could be 
seen. Surprisingly, this induction of CYP3A4 was even more prominent with budesonide 
compared to rifampicin.  
PXR is known to be expressed in the human intestine. Therefore, budesonide treatment might 
lead to increased intestinal levels of P-gp and CYP3A4. Thus, potential drug-drug interactions 
have to be taken into account, when substrates of P-gp or CYP3A4 are co-administered. On the 
other hand, the intestinal expression level of PXR itself is a factor that can vary in diseases, such as 
ulcerative colitis, where PXR has been shown to be downregulated (Langmann et al., 2004). 
Consequently, results from in vivo studies in healthy subjects cannot directly be applied to the 
situation in patients with IBD.  
In conclusion, we have shown in this study that budesonide has the potential to influence the 
expression of intestinal MDR1 in vitro. The investigated intestinal cell lines showed opposing 
regulatory effects of this transporter. Further studies have to be carried out to evaluate the impact 
of glucocorticoid treatment on intestinal P-gp expression in vivo.  
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4.2.1 Abstract 
Budesonide, a glucocorticoid with a high first-pass metabolism, is used for the oral treatment of 
inflammatory bowel disease. Cytochrome P450 3A4 (CYP3A4) is an enzyme involved in the 
metabolism of numerous drugs, including budesonide. Since inhibition or induction of CYP3A4 
is often the cause of drug-drug interactions we analysed how budesonide affects the activity and 
expression of this enzyme. CYP3A4 activity was assessed by the metabolism of a luminogenic 
substrate (luciferin-benzylether) using recombinant human CYP3A4 protein. We observed no 
inhibition of the metabolism in the presence of budesonide at concentrations up to 25 μM. 
Induction experiments in human LS180 colon carcinoma cells showed an increased expression of 
CYP3A4 mRNA after budesonide treatment. Transactivation assays revealed that budesonide 
activates the CYP3A4 promoter via the pregnane X receptor (PXR). In mice, oral budesonide 
administration (25 mg/kg) for 4 days induced the murine homolog Cyp3a11 in the intestine 3-
fold, whereas liver expression was notably less influenced. In knockout mice devoid of PXR, 
budesonide-mediated inductions were reduced compared to wild-type mice. In conclusion, we 
could demonstrate that budesonide is not an efficient inhibitor but rather an inducer of CYP3A 
via a PXR-mediated mechanism. In vivo, however, oral budesonide administration to mice 
showed only modest gene induction, which occurred mainly in the intestine. Therefore, the risk 
for budesonide-mediated drug interactions seems to be low but cannot be ruled out entirely. 
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4.2.2 Introduction 
Glucocorticoids are substances with strong anti-inflammatory properties mediated through 
specific activation of the glucocorticoid receptor (GR). However, beside their high affinity for the 
GR, it has been shown for some glucocorticoids that they are also low-affinity ligands of the 
pregnane X receptor (PXR, NR1I2) (Lehmann et al., 1998; Sheppard, 2002). PXR is a 
promiscuous transcription factor expressed in liver and intestine that induces the expression of 
genes involved in xenobiotic metabolism and transport, thereby stimulating the detoxification 
and elimination of endogenous substances, drugs, and other xenobiotics (Geick et al., 2001; 
Pascussi et al., 2003). One of the PXR target genes is cytochrome P450 3A4 (CYP3A4), which 
encodes one of the most important Phase I drug-metabolizing enzymes in humans. Since more 
than 50% of all prescribed drugs are CYP3A4 substrates, induction (or inhibition) of this enzyme 
are often the cause of clinically relevant drug-drug interactions (Lin and Lu, 1998). Therefore, it 
is a relevant characteristic of a drug to be able to induce CYP3A4 expression or, on the other 
hand, inhibit CYP3A4 activity. 
Studies in rodents revealed that treatment with the glucocorticoid dexamethasone induces the 
expression of the efflux transporter P-glycoprotein and the metabolizing enzyme cytochrome 
P450 3A (Lin et al., 1999; Jin et al., 2006). They further showed that these inductions are PXR-
mediated and eventually lead to changes in the pharmacokinetics of co-administered drugs due to 
an enhanced drug clearance. Consequently, co-application of a PXR-activating ligand might 
reduce or even abolish the efficacy of a given drug therapy.  
Budesonide is a synthetic glucocorticoid that is amongst others used orally in patients with 
inflammatory bowel disease. It acts locally in the gut lumen where it is readily absorbed, followed 
by extensive pre-systemic metabolism, primarily by CYP3A4 (Jonsson et al., 1995) (Lu et al., 
2008). As a consequence, budesonide has high topical anti-inflammatory activity, but 
considerably lower systemic activity than conventional glucocorticoids (Thalen et al., 1989). So 
far there is only limited information about the impact of budesonide treatment on the activity 
and expression of drug-metabolizing enzymes. Though, induction of CYP3A5 by budesonide 
through a GR-mediated pathway in the human lung adenocarcinoma cell line A549 has been 
reported (Hukkanen et al., 2003). In the colon carcinoma cell line Caco-2, we recently found 
that budesonide led to an induction of CYP3A4 when the cells were transfected with human PXR 
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(Maier et al., 2007). However, there is no direct evidence yet that budesonide is an activator of 
PXR and, in turn, can induce drug-metabolizing enzymes in vivo. The rationale of the present 
study was therefore to clarify whether this glucocorticoid can induce CYP3A in vitro and in vivo, 
and to assess if PXR activation is involved. Since budesonide is an excellent CYP3A4 substrate, 
we further determined whether it could inhibit the activity of this enzyme. All together, this 
knowledge might help to assess the risk for possible CYP3A4 interactions mediated by 
budesonide. 
 
4.2.3 Methods 
Materials 
Budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, and pregnenolone-16α-
carbonitrile (PCN) were from Sigma Aldrich (St Louis, MO, USA). Rifampicin was from Fluka 
Chemie (Buchs SG, Switzerland). The pGL3-CYP3A4-XREM (-372/+7.8 kb) luciferase reporter 
construct was a kind gift from Dr. Richard Kim (Vanderbilt University, Nashville, USA), the 
pCDG-hPXR expression vector was generously provided by Dr. R.M. Evans (The Salk Institute 
for Biological Studies, La Jolla, CA). The pCMV-mPXR was obtained from Dr. B. Forman 
(Beckman Research Institute of the City of Hope National Medical Center, Duarte, California). 
The LS180 cell line was purchased from ATCC (Manassas, USA). 
 
Determination of CYP3A4 Inhibition 
The inhibitory potency of budesonide on CYP3A4 metabolism was measured using the P450-
Glo assay for CYP3A4 from Promega (Madison, WI, USA). Assays were carried out according to 
the instructions of the manufacturer. Briefly, reactions were performed in 96 well plates in a total 
reaction volume of 50 µL. Each reaction contained 1 pmol of CYP3A4 (cell membranes prepared 
from baculovirus-infected insect cells). As a CYP3A4 substrate luciferin-benzylether at 30 µM, 
which is metabolized to luciferin, was applied. Budesonide and ketoconazole (control inhibitor of 
CYP3A4) were used between 0.025 and 25 µM. Control reactions with no inhibitor (0.1% 
acetonitrile) and with membranes devoid of CYP3A4 (for background measurements) were 
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performed in parallel. After a preincubation of 10 minutes reactions were started by adding a 
NADPH regeneration solution. Metabolic reactions were carried out at room temperature for 60 
minutes. After adding a luciferin detection reagent the reactions were stopped and CYP3A4 
activity could be assessed by measuring the emerging luminescence.  
 
Measurement of CYP3A4 mRNA Induction in Human Intestinal Cells 
The procedure for measuring CYP3A4 induction in LS180 cells was described before (Maier et 
al., 2007). Briefly, cells were treated with budesonide, dexamethasone, rifampicin or vehicle 
(0.25% DMSO) for 48 hours. Total RNA was extracted and 0.5 µg was reverse transcribed. Real-
time PCR analysis (TaqMan) was carried out on a 7900HT Sequence Detection System (Applied 
Biosystems) using qPCR Mastermix Plus from Eurogentec (Seraing, Belgium). Sequences of 
primers and probes have been reported by us (Maier et al., 2007). For absolute quantification 
external standard curves were used. Expression of CYP3A4 was normalized to the expression of 
GAPDH. Drug treatments did not significantly influence GAPDH levels.  
 
CYP3A4 Reporter Gene Assay 
LS180 cells were seeded in 96 well plates, incubated overnight, and transfected with 75 ng/well of 
nuclear receptor expression vector (pCDG-hPXR or pCMV-mPXR), 210 ng/well of the CYP3A4 
luciferase reporter construct (pGL3-CYP3A4-XREM), and 15 ng/well of the renilla luciferase 
expression control vector (pRL-TK; Promega, Madison, WI, USA), using Exgen500 in vitro 
transfection reagent (Fermentas, St. Leon-Rot, Germany) in 150 mM NaCl. After overnight 
transfection, the drugs (dissolved in DMSO) were added to the plates and after 48 hours, cells 
were lysed with Passive Lysis Buffer (Promega, Madison, WI, USA). The reporter activities of 
firefly luciferase and renilla luciferase in the cell lysates were determined using the Dual-Luciferase 
Reporter (DLRTM, Promega, Madison, WI, USA) Assay System. Luminescence was recorded on 
a Mithras LB940 microplate reader (Berthold Technologies, Bad Wildbad, Germany). Cells 
without hPXR or mPXR transfection did not yield significant luminescent signals.  
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Measurement of Cyp3a11 and Oatp2 mRNA Induction in Mice 
Mice were housed and handled according to institutional guidelines complying with Dutch 
legislation. Pxr-knockout mice were kindly provided by Dr. R.M. Evans (The Salk Institute for 
Biological Studies, La Jolla, CA) and were crossed back to a homogeneous (>99%) FVB genetic 
background. Mice used in experiments were male, between 8 and 15 weeks of age and kept in a 
temperature-controlled environment with a 12-h light/dark cycle. They received a semisynthetic 
diet (Reference diet 20% casein, Hope Farms, Woerden, The Netherlands) and acidified water ad 
libitum. 
For induction studies, wild-type and Pxr-knockout mice were given an oral dose of 
dexamethasone or budesonide (both 25 mg/kg), or vehicle (corn oil) for 4 consecutive days. Each 
group consisted of 4 animals. On day 5, mice were sacrificed, intestines and livers were isolated 
and immediately placed in RNAlater (Qiagen). Total RNA was extracted using the RNeasy mini 
kit (Qiagen) and 1 µg was reverse transcribed using Superscript II (Invitrogen, Carlsbad, CA) and 
random hexamers (Applied Biosystems) according to the supplier's protocols. Real-time PCR was 
performed on a 7500 real-time cycler system (Applied Biosystems) using SyBr Green PCR master 
mix and QuantiTect Primer Assays (Qiagen) for the genes of interest (Cat.No.: QT00170590 
(Cyp3a11), QT01065232 (Oatp2), QT00095242 (ß-actin)). Then 45 PCR cycles (denaturation 
at 95°C for 15 s and annealing/extension at 60°C for 1 min) were performed. All samples were 
run in duplicates and non-reverse-transcribed RNA served as a negative control. Analysis of the 
data was done by relative quantification using the 2-∆∆Ct method as described (Livak and 
Schmittgen, 2001). Briefly, for all samples Ct values of the target genes were normalized to the Ct 
values of ß-actin and subsequently normalized to the values of vehicle treatment. This was 
independently done for both wild-type and Pxr-knockout mice. ß-actin was chosen as a reference 
gene since the expression was not influenced by drug treatment.  
 
Statistical analysis 
Data from control and test groups were analysed for statistical significance using Student`s t-test 
(unpaired, two-tailed). p<0.05 was considered statistically significant. 
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4.2.4 Results and Discussion 
In this study we addressed the question whether the glucocorticoid budesonide can inhibit the 
activity or induce the expression of the drug-metabolising enzyme CYP3A4. Both inhibitors and 
inducers can lead to alterations in the pharmacokinetics of co-administered CYP3A4 substrates 
resulting in potential drug-drug interactions (Lin and Lu, 1998). Regarding this problem only 
little information is available about budesonide.  
We used recombinant CYP3A4 protein and a luminogenic CYP3A4 substrate to assess the 
inhibitory potency of this glucocorticoid in vitro. When testing budesonide concentrations up to 
25 µM the activity of CYP3A4 was not inhibited (Figure 24). At higher concentrations we started 
to observe poor solubility of the drug. It thus seems unlikely that much higher free drug 
concentrations occur in vivo. Ketoconazole, a known potent CYP3A inhibitor in vivo, displayed 
an ideal inhibition curve in this test system (Figure 24). The IC50 we found for ketoconazole 
(about 0.5 µM) was on the high end, but still well within the range reported for various CYP3A4 
substrates. So far the lack of clinical interactions with budesonide has been attributed to the low 
systemic concentrations (Edsbacker and Andersson, 2004). Our experiments show that even at 
high drug concentrations there is no significant inhibition of metabolism of a model substrate by 
CYP3A4. Although we cannot fully exclude that budesonide-mediated inhibition might occur for 
some other CYP3A4 substrates, our data do suggest that budesonide will not substantially inhibit 
the metabolism of other drugs in vivo. 
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Figure 24 Determination of the effect of budesonide on CYP3A4 acitvity. CYP3A4-containing cell membranes were 
incubated with budesonide or ketoconazole (control inhibitor of CYP3A4). Luciferin-benzylether was applied as a 
CYP3A4 substrate and the metabolism to luciferin was analysed after 60 minutes by measuring the resulting 
luminescence. Data points represent mean values +/- SEM (n = 4). For ketoconazole a sigmoidal inhibition curve 
could be fitted. 
 
For assessing whether budesonide is an inducer of CYP3A4 we applied LS180 human intestinal 
cells, a cell line which is effectively used to screen substances for their ability of PXR-mediated 
gene induction (Gupta et al., 2008). Here, budesonide demonstrated a dose-dependent induction 
of the endogenous CYP3A4 mRNA (Figure 25). Dexamethasone, on the other hand, did not 
change the expression of this gene.  
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Figure 25 Effect of dexamethasone and budesonide on the expression of CYP3A4 mRNA in intestinal cells. LS180 
cells were incubated with increasing concentrations (1, 10, 25 µM) of dexamethasone and budesonide for 48 h. 
mRNA expression of CYP3A4 was measured by real-time PCR and normalised to the expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). DMSO (control) and rifampicin (10 µM) were used as negative and positive 
controls, respectively. Results are mean values (± SD) pooled from 3 independent experiments (each n = 3). * p < 
0.05 vs control (using Students unpaired, two-tailed t test). 
 
PXR transactivation assays in LS180 cells transfected with a human PXR expression vector and a 
CYP3A4 promoter-containing reporter construct revealed that budesonide is a good activator of 
human PXR (Figure 26a). We observed a more than 5-fold increase of the reporter gene activity 
whereas all other glucocorticoids, including dexamethasone, did not show a significant activation 
in this intestinal cell line. When transfecting mouse PXR, both dexamethasone and budesonide 
activated the CYP3A4 promoter around 6-fold (Figure 26b). Budesonide thus activates both 
human and mouse PXR. The observed species difference for dexamethasone is consistent with 
previous reports that dexamethasone is a much better activator of mouse Pxr than human PXR 
(Moore et al., 2000).  
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Figure 26 Transactivation of the CYP3A4 promoter by human and mouse PXR in the presence of glucocorticoids. 
LS180 cells were cotransfected with either human PXR (A) or mouse PXR (B) and a human CYP3A4 promoter-
driven firefly-luciferase construct together with a renilla-luciferase expression control vector. Cells were incubated 
with different glucocorticoids (100 µM), rifampicin (10 µM), pregnenolone-16α-carbonitrile (PCN, 10 µM), or 
DMSO (control) for 48 h, followed by measurement of the luciferase activity. The firefly-luciferase signal was 
normalised to the renilla-luciferase signal. Results are expressed as mean values ± SD (n = 3). * p < 0.05 vs control. 
 
Given these results, budesonide might be a likely candidate for drug-drug interactions, due to its 
ability to activate PXR and induce CYP3A4 expression. However, a characteristic quality of 
budesonide is its extensive first pass metabolism leading to rapid drug degradation and an 
estimated systemic availability in humans of only 10% after oral treatment (Lundin et al., 2003). 
Therefore we investigated whether these pharmacokinetic properties resulted in a reduced or even 
abolished ability to induce PXR-target genes in vivo.  
This question was addressed by assessing how a 4-day oral drug treatment influenced the 
expression of the mouse PXR target gene Cyp3a11 in wild-type and Pxr-knockout mice. In line 
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with the activation of mouse PXR in vitro, both budesonide and dexamethasone induced 
Cyp3a11 expression in the duodenum of wild-type mice (around 3-fold, Figure 27a). Induction 
was also observed in the jejunum, albeit less pronounced (around 2-fold). In Pxr-knockout mice, 
however, there was still a treatment-related induction of Cyp3a11 observable. Especially for 
dexamethasone, the induction levels were at least as high in the absence of PXR. In contrast, with 
budesonide induction levels did decrease significantly in Pxr-knockout mice in both duodenum 
and jejunum (p < 0.05), although in duodenum they were not completely reduced to the 
expression levels of vehicle treatment (Figure 27a). These data suggest that budesonide-mediated 
upregulation of intestinal Cyp3a11 is substantially mediated by PXR, but that dexamethasone-
mediated induction is less dependent on PXR.  
 
Figure 27 Intestinal and hepatic mRNA expression in mice after dexamethasone and budesonide treatment. The 
drugs (25 mg/kg/day) or corn oil (control) were given orally to wild-type (wt) and Pxr-knockout (ko) mice for 4 
days. Expression levels were determined with real-time PCR and normalised to the expression of ß-actin. A: mRNA 
expression of Cyp3a11 in duodenum and jejunum. B: mRNA expression of Cyp3a11 and Oatp2 (Slco1a4) in liver. 
Results are normalised to vehicle treatment and displayed as mean values ± SD (n = 4). * p < 0.05 vs control. Note 
that basal expression levels of Cyp3a11 in duodenum, jejunum and liver were higher in Pxr-knockout mice 
compared to wild-type mice (1.5, 1.2, and 6.6-fold, respectively). Basal hepatic Oatp2 levels were 12-fold lower in 
Pxr-knockout mice compared to wild-type mice. 
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The induction of mouse Cyp3a11 has been attributed to various other transcription factors 
besides PXR, such as AhR, CAR, and Nrf2 (Cheng et al., 2005). Whether any of these 
transcription factors is indeed activated by glucocorticoids is, to our knowledge, still unknown. 
For human CYP3A5 (and CYP2C9) a direct effect of the GR on the induction of these genes has 
been shown (Schuetz et al., 1996), (Gerbal-Chaloin et al., 2002). A role for the GR in the 
mechanism of CYP3A4 induction has been discussed, although this gene contains no obvious 
consensus binding site for the GR (Pascussi et al., 2003). Data from GR-deficient mice suggest 
that the GR is not required for the induction of mouse CYP3A (Schuetz et al., 2000). 
Nevertheless, the GR seems to be indirectly involved in CYP induction by increasing the 
expression of PXR, RXR and CAR, thereby leading to a potentiation of xenobiotic-mediated 
CYP inductions (Huss and Kasper, 2000), (Pascussi et al., 2000). It may therefore be that, next to 
Pxr, also GR contributes to the budesonide-dependent expression changes we observed in Figure 
27. 
Since PXR is a transcription factor showing high expression in intestine and liver (Lehmann et 
al., 1998), we further analysed how oral drug treatment affected the expression of PXR target 
genes in liver (Figure 27b). There was a marked quantitative difference between the two 
glucocorticoids: dexamethasone induced the expression of hepatic Cyp3a11 mRNA 27-fold, 
whereas budesonide showed only a modest increase in the expression of this gene (less than 2-
fold). In Pxr-knockout mice budesonide treatment did not influence hepatic Cyp3a11 expression 
at all, and dexamethasone showed a much reduced (albeit still significant) ~2-fold induction. We 
also measured the expression of the presumably more specific PXR target gene organic anion 
transporting polypeptide 2 (Oatp2, Slco1a4) (Cheng et al., 2005). After drug treatment of wild 
type mice, hepatic expression levels of this gene were only induced by dexamethasone (4.5-fold 
induction, Figure 27b). Budesonide showed no effect on hepatic Oatp2 expression in wild-type 
mice, and - for unknown reasons - even downregulated Oatp2 in Pxr-knockout mice.  
The apparent discrepancy in hepatic gene induction between the two investigated glucocorticoids 
might be attributable to their differences in systemic exposure, with only low amounts of 
budesonide reaching the liver compared to dexamethasone. Note, however, that our data do 
suggest that still some budesonide reaches the liver, in view of the effects of budesonide on 
hepatic gene expression (Figure 27b). One study that analysed budesonide degradation in tissue 
fractions from human liver and colon suggested that this drug is predominantly metabolised in 
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hepatic tissue (Cortijo et al., 2001). On the other hand, two recent publications revealed that 
intestinal CYP3A4 expression also has a high impact on budesonide pharmacokinetics (Seidegard 
et al., 2008; Ufer et al., 2008). Regarding the pharmacokinetics of oral budesonide in mice not 
much is known, but the rates and routes of budesonide metabolism seem to be very similar in 
mice and humans, implying the relevance of mouse models in this respect (Edsbacker et al., 
1987). The data from our study suggest that budesonide has a strongly reduced induction 
capacity in the liver, possibly due to its high presystemic metabolism. However, locally in the 
intestine it exerts similar effects as a conventional glucocorticoid such as dexamethasone. 
Degradation of budesonide in enterocytes is probably not fast enough to significantly affect 
intestinal gene induction. Consequently, its pharmacological effects (whether GR- or PXR-
mediated) seem to be mostly restricted to the intestinal tract, with a very low systemic 
component. 
For the extrapolation of our results to the human situation, some aspects have to be taken into 
account. In our in vivo study we used high drug doses (25 mg/kg/d), comparable to studies where 
gene induction by glucocorticoids was investigated in mice. In patients suffering from chronic 
intestinal inflammation (e.g. Crohn`s Disease), usually an oral dose of 9 mg budesonide per day 
is applied (Spencer and McTavish, 1995), which is lower than the mouse dose, even after 
correction for metabolic weights. Another important factor is the way the drug is delivered. We 
suspended the drug in corn oil before oral administration to mice, allowing the drug to be 
absorbed along its way through the gastrointestinal tract. Patients, on the other hand, generally 
receive a controlled release formulation of the drug (Edsbacker et al., 2002). This ensures that 
budesonide is mainly released in the distal small intestine and the colon, where the predominant 
sites of inflammation are located. Therefore, induction of CYP3A4 (or other PXR-target genes) 
might occur primarily at the site of drug release, where local concentrations can be very high. 
These high concentrations are necessary for PXR-mediated effects, given that it is a receptor with 
only low affinity for glucocorticoids (Sheppard, 2002). 
When analysing clinical studies, there seems to be no particular evidence so far that budesonide is 
the cause of drug-drug interactions. However, since the degradation of budesonide itself is 
primarily CYP3A4/5-mediated (Jonsson et al., 1995), (Lu et al., 2008), induction of CYP3A4 by 
rifampicin resulted in virtually abolished budesonide plasma levels (Dilger et al., 2005). In this 
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respect it might be possible that budesonide could increase its own metabolism by inducing 
intestinal CYP3A4 expression. Indeed, peak plasma concentrations of the main metabolites 6β-
hydroxybudesonide and 16α-hydroxyprednisolone were both found to be slightly increased after 
7 days of budesonide treatment compared to single-dose administration (Dilger et al., 2006). It is 
therefore imaginable that the metabolism of a co-administered CYP3A4 substrate could be 
enhanced as well, provided that both drugs are absorbed in similar regions of the gastro-intestinal 
tract.  
In conclusion, we showed that budesonide activates both human and mouse PXR in vitro. After 
oral administration, a local induction of PXR-target genes in the intestine could occur, whereas 
hepatic gene expression is most likely not much influenced. Therefore, the risk for budesonide-
mediated drug interactions appears to be low, but cannot be ruled out. Only clinical studies can 
assess the possibility for drug interactions in humans.  
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4.3 Stable Transfection of hPXR in Caco-2 Cells 
 
4.3.1 Abstract 
Background and Purpose: Caco-2 cells represent a good model for intestinal absorption studies. 
Induction of PXR target genes such as P-gp and CYP3A4 is an important determinant of 
intestinal drug absorption. Caco-2 cells are not inducible by ligands of PXR. To reconstitute 
functional active PXR we aimed to establish a stable PXR-transfected Caco-2 cell system.  
Experimental Approach: Caco-2 cells were stable transfected with the full ORF expression PXR 
plasmid. PXR mRNA expression of transfected clones was measured using real-time PCR, 
whereas PXR protein expression was shown by Western blot. Functional activity of PXR was 
assessed by measuring the induction of PXR target genes P-gp and CYP3A4. Changes in P-gp 
and CYP3A4 expression was measured using RT-PCR, Western blot analysis and measurement 
of functional P-gp activity. 
Key Results: PXR mRNA and protein expression was increased in stable transfected PXR clones. 
The PXR target genes P-gp and CYP3A4 were significantly induced on mRNA level after 
induction with the PXR-ligand rifampicin. PXR-mediated induction of P-gp protein expression 
could not be quantified but Western blot analysis revealed a highly increased P-gp expression in 
PXR-transfected cells compared to wild-type cells. Induction of P-gp on functional level showed 
conflicting results. Efflux of the P-gp substrate R123 was increased after induction whereas 
remaining R123 did not confirm this finding.  
Conclusions and Implications: We were able to generate a stable PXR-transfected Caco-2 cell 
line which expresses higher levels of P-gp than wild-type cells. However, the induction potencies 
of this system have to be investigated in further studies. 
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4.3.2 Introduction 
The intestine constitutes a barrier function against xenobiotics and toxins. Intestinal epithelial 
cells form the first barrier for orally applied drugs. Beyond physicochemical properties of the drug 
itself, intestinal active extrusion and drug metabolism are important mechanisms that influence 
oral bioavailability of drugs. The impact of intestinal export-transport and metabolism in drug 
therapy has been extensively described in literature (Floren et al., 1997), (Hebert et al., 1992). 
Studies in patients receiving cyclosporine a (CsA) or tacrolimus have shown that gut metabolism 
and export-function significantly alter bioavailability of these drugs. CsA and tacrolimus both are 
substrates of the phase I metabolic enzyme cytochrome P450 3A4 (CYP3A4) and the export 
transporter P-glycoprotein (P-gp), which belongs to the ATP-binding-cassette transporters (ABC-
transporter). CYP3A4 and P-gp share a broad overlap in substrate specificity. In parallel, they are 
both regulated by a large amount of drugs. Human pregnane X receptor (hPXR), a member of 
the orphan nuclear receptor family, was shown to be responsible for transcriptional regulation of 
P-gp and CYP3A4 (Bertilsson et al., 1998), (Geick et al., 2001). hPXR also called steroid and 
xenobiotic receptor (SXR) or pregnane-activated receptor (PAR) is encoded by the NR1I2 gene. 
Different isoforms of PXR are described, whereas PXR.1 is the most abundant splice variant. All 
of these isoforms contain a DNA-binding domain (DBD) which contains a zinc-finger motive at 
the N-terminal, and a ligand-binding domain (LBD) at the C-terminal (Kliewer et al., 1998), 
(Lamba et al., 2004). The LBD domain is designed for binding of a broad range of ligands 
(Watkins et al., 2001). Endogenous and synthetic steroids are known ligands of PXR but 
xenobiotics such as rifampicin, nifedipine, clotrimazole or paclitaxel also have been shown to 
activate hPXR (Kliewer et al., 1998), (Blumberg et al., 1998), (Lehmann et al., 1998), (Synold et 
al., 2001). Upon activation PXR builds a heterodimer with retinoid-X-receptor-α (RXRα) and 
translocates to the nucleus. In the nucleus the heterodimer binds to nuclear response elements on 
the promoter of the target gene. PXR:RXRα heterodimer binding sites on the promoter of 
CYP3A4 and P-gp were detected (Blumberg et al., 1998), (Geick et al., 2001). The following 
induction of CYP3A4 and P-gp then leads to increased metabolism or efflux of xenobiotics. This 
regulation is important in the intestine where orally applied drugs are absorbed. Caco-2 cells are a 
good in vitro model for the intestine (Hidalgo et al., 1989). Unfortunately, Caco-2 cells express 
only low levels of endogenous PXR. Additionally, the known PXR activator rifampicin is not able 
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to induce PXR target genes in Caco-2 cells (Pfrunder et al., 2003). In a previous study, we 
transiently transfected Caco-2 cells with PXR and could detect a slight induction of PXR target 
genes after induction with rifampicin (Maier et al., 2007). The aim of the present study was to 
establish a stable model of PXR-transfected Caco-2 cells in order to have PXR-inducible Caco-2 
cells which should represent a more similar model of the intestinal epithelium. 
 
4.3.3 Methods 
Materials 
The Full ORF Expression vector of PXR (IOH34726-pT-Rex-DEST30) was purchased from the 
Deutsches Ressourcenzentrum für Genomforschung GmbH. Geneticin (50 mg/ml) was 
purchased from Invitrogen. Rifampicin (Sigma-Aldrich) was dissolved in dimethylsulfoxide 
(DMSO) and rhodamine 123 (Molecular Probes, Eugene, OR, USA) was dissolved in ethanol.  
 
Cell Culture: see chapter 2.1. 
Real-time RT-PCR: see chapter 2.2 
Sequences for primers and probes are described in Table 1. 
Western Blot Analysis: see chapter 2.3 
Efflux Assay: see chapter 2.6 
Transfection 
The Full ORF Expression vectors of PXR (IOH34726-pT-Rex-DEST30) was purchased from 
the Deutsches Ressourcenzentrum für Genomforschung GmbH. The empty vector (-pPXR), 
which served as negative control, was obtained by cutting the PXR plasmid (+pPXR) with the 
restriction enzymes EcoRV and Mlu I followed by purification on a 0.5% agarose gel. The cut 
ends were blunt-ended with T4 DNA polymerase and self-circulated with T4 DNA ligase. For 
stable transfection, Caco-2 cells were seeded on 6-well-plates in Dulbecco’s modified Eagle’s 
medium with Glutamax-I, supplemented with 10% fetal bovine serum, 1% non-essential amino 
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acids, 1% sodium pyruvate, 50 µg/ml gentamycin. Transfection was started when cells reached a 
confluency of ~60%. Transfection was performed with LipofectamineTM 2000 (Invitrogen) 
during 72 hours following the manufacturer’s protocol using 4 µg Plasmid DNA and 10 µl 
LipofectamineTM 2000 each in a volume of 250 µl Opti-MEM I (Invitrogen) and 2 ml DMEM 
without gentamycin per well. After 72 hours, cells were diluted 1:40 into 10 mm Petri dishes and 
the selection antibiotic geneticin (Invitrogen) was added in a concentration of 1.5 mg/ml. The 
appropriate concentration of the resistance antibiotic geneticin was previously determined by a 
killing curve in Caco-2 wt cells using different concentrations of geneticin over 10 days. Every 3-
4 days DMEM with geneticin was replaced. After 2 weeks clones were picked using Scienceware® 
Cloning discs (Sigma-Aldrich) and further cultured in 24-well plates with a geneticin 
concentration of 1 mg/ml. 
Each clone was cultured over 6 passages and mRNA expression of PXR was measured. Clones 
expressing high levels of PXR were used for induction studies with rifampicin. Induction of 
MDR1 and CYP3A4 mRNA expression was quantified using real-time RT-PCR. The clone with 
the best induction on mRNA level was chosen for further evaluation on protein and on 
functional level. 
 
4.3.4 Results 
Expression of PXR 
Stable transfection of PXR into Caco-2 cells was performed. In order to measure the extent of 
transfection PXR mRNA expression was analysed in PXR-transfected clones compared to empty-
vector-transfected Caco-2 cells. The expression of PXR mRNA in PXR-clones was about 30-fold 
higher compared to control cells (Figure 28A). In addition to mRNA expression PXR protein 
expression was detected using western blot analysis (Figure 28B). As shown in Figure 28B an 
incresase in PXR expression was detected in PXR-transfected clones compared to wt Caco-2 cells. 
LS180 cells were used as positive control for PXR detection, as shown in Figure 28B basal PXR 
expression level is higher in LS180 cells compared to Caco-2 wt as well as stable PXR-transfected 
Caco-2 cells. 
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Figure 28 (A) mRNA expression of PXR in Caco-2 cells after transfection with empty vector (-pPXR) and PXR 
vector (+pPXR). mRNA expression was determined by quantitative real-time PCR. PXR expression is expressed 
relatively to empty-vector transfected cells. Data represent mean ± s.e.m. of 3 independent assays (n=9) ***p< 0.001 
vs –pPXR. (B) Western blot analysis for PXR protein expression in Caco-2 wt, PXR-transfected clones and LS180 
cells. 
 
Induction of MDR1 and CYP3A4 
In order to check functional activity of transfected PXR, induction studies with rifampicin were 
performed for 3 days. Expression of the PXR-target genes MDR1 (Figure 29A) and CYP3A4 
(Figure 29B) was measured on mRNA level. In PXR-clones we observed a significant induction 
(ca 1.6 fold) of MDR1 mRNA expression after induction with rifampicin, while in empty-vector 
transfected clones, no alteration in MDR1 mRNA expression was observed. A similar effect was 
observed on CYP3A4 mRNA expression after rifampicin induction (ca 1.9 fold). However, 
regarding the low level of CYP3A4 expression in Caco-2 cells, this result has to be considered 
carefully. MDR1 Protein expression after induction with rifampicin was analysed using western 
blot technique (Figure 29C). Western blot was difficult to quantify and the assay was suboptimal. 
Unusually, P-gp protein expression was only poorly detectable in Caco-2 wild-type and LS180 
cells. In Caco-2 wild-type cells P-gp expression did not alter after treatment with the inductor. A 
slight difference in P-gp expression after rifampicin treatment was detected in the positive control 
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LS180 cells. Unfortunately, in PXR-transfected Caco-2 cells, the inductor effect of rifampicin 
could not be quantified in this Western blot analysis. However, this Western blot analysis clearly 
showed that PXR-transfected Caco-2 cells have definitely a higher expression level of P-gp 
compared to wild-type cells even when lower amounts of protein were added. 
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Figure 29 mRNA expression of PXR target genes MDR1 (A) and CYP3A4 (B) after 72 hours induction with 
rifampicin 10 µM in Caco-2 cells stable transfected with empty vector (-pPXR) and PXR vector (+pPXR). mRNA 
expression was determined by quantitative real-time PCR. Results are normalised to the respective control treatment 
(vehicle only). Data represent mean ± s.e.m. of 3-5 assays (n=6-15) *p<0.05 (C) Western blot analysis: Protein 
expression of P-gp after 72 hours induction with rifampicin or vehicle only in Caco-2 wild-type cells, PXR-clones 
and LS180 cells. 
 
Functional Activity of P-gp 
Functional activity of P-gp in Caco-2 wild-type, PXR-clones and LS180 cells was measured using 
Rhodamine (R123) as substrate of P-gp. Cells were induced for 3 days with rifampicin and the 
change of P-gp activity was measured using R123-Efflux-assay. Efflux and remaining 
accumulation of R123 after 1 hour efflux-period was measured compared to cells where P-gp 
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activity was inhibited with verapamil. More efflux and less remaining accumulation means higher 
P-gp activity. Efflux of R123 was elevated in Caco-2 PXR-clones and LS180 cells after rifampicin 
induction, while no change was detectable in Caco-2 wild-type cells (Figure 30A). However, 
remaining accumulation of R123 is slightly but not significantly lower (Figure 30B).  
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Figure 30 Functional activity of P-gp after 3 days induction with rifampicin 10 µM in Caco-2 wild-type, PXR-
transfected Caco-2 cells and LS180 cells. Efflux-assay was performed with R123 (0.5 µM) for 1 hour. Efflux of R123 
(A) and remaining substance (B) was measured. Data represent R123 fluorescence relative to verapamil (100 µM)-
treated cells normalised to control. Results are expressed as mean±s.e.m. (n=5-6). *p<0.05, **p<0.01 
 
4.3.5 Discussion 
CYP3A4 and P-gp play an important role in drug absorption and metabolism. Intestinal 
expression of these two proteins can limit bioavailability of orally applied drugs. Previous studies 
demonstrated that CYP3A4 and P-gp are regulated via the orphan nuclear receptor PXR. PXR 
exhibits a broad range of ligands and consequently is activated by a large amount of drugs. PXR 
activation and further transcriptional regulation of CYP3A4 and P-gp possibly diminish 
bioavailability of administered drugs and drug-drug interaction could be the consequence. 
Intestinal models to assess this interaction potential in vitro are required. LS180 cells represent a 
good model for intestinal induction experiments (Pfrunder et al., 2003). Caco-2 cells are an 
established model for intestinal drug-transport studies (Hidalgo et al., 1989), since they form a 
tight monolayer, and the expression level of ABC-transporters is similar to that of human jejunal 
tissue (Taipalensuu et al., 2001). Unfortunately, Caco-2 cells express only low levels of hPXR and 
PXR target genes CYP3A4 and P-gp are not inducible with rifampicin, suggesting non-functional 
PXR-expression in Caco-2 cells (Pfrunder et al., 2003). Transfection of hPXR into Caco-2 cells 
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might serve as a good intestinal in vitro model for transport and induction in the intestine. In an 
earlier study, we transiently transfected PXR into Caco-2 cells and could observe a significant 
induction of MDR1 and CYP3A4 mRNA expression, which was still lower than the one 
observed in LS180 cells (Maier et al., 2007). In this study, a stable PXR-transfected Caco-2 
model was intended to establish. 
PXR transfection led to a stable transfected cell line with a 35-fold increase in PXR mRNA 
expression compared to control cells. PXR protein expression was also increased after transfection 
but not to the same extent as mRNA. Functional activity of PXR was checked via induction of 
PXR target genes with rifampicin. The induction with rifampicin led to a significant increase in 
CYP3A4 and MDR1 mRNA expression. However this effect is lower than the induction effect 
on MDR1 and CYP3A4 in LS180 cells (data not shown). This might be explained by the fact 
that LS180 cells express a basic PXR level (Figure 28B) that is still higher than in stable 
transfected cells. Induction of P-gp protein after rifampicin treatment was hardly detectable in 
PXR-transfected Caco-2 cells and also in the positive control LS180 cells. Probably changes in P-
gp protein expression were small and the sensitivity of the present assay apparently was not 
adequate. 
Elevated functional activity of P-gp after rifampicin induction was assessed by rhodamine 123 
efflux assays. Increased efflux of the P-gp substrate R123 was observed after induction in PXR-
clones and LS180 cells. Unfortunately, residual accumulation of R123 after one hour efflux could 
not confirm the effects seen in the efflux. A small but not significant decrease in R123 
accumulation after rifampicin induction was observed in PXR-transfected clones as well as in the 
positive control LS180 cells. Induction effects on the PXR target gene P-gp were not as 
pronounced as in LS180 cells as we showed in earlier studies. A possible explanation for this 
observation could be the different cell system. PXR-mediated induction requires co-factors such 
as RXR for heterodimerisation upon activation. Our Caco-2 cells express RXR mRNA, but 
possible differences in co-factors expression and function in Caco-2 cells compared to LS180 cells 
is not clarified and might play a role in the observed small induction of PXR target genes. 
Transfection of hPXR into Caco-2 cells was earlier described by Korjamo et al. (Korjamo et al., 
2005), (Korjamo et al., 2006). Comparable to our results, they only could observe small 
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inductions of P-gp in hPXR-transfected Caco-2 cells and these results were predominantly 
achieved after 7-14 days induction with rifampicin.  
Taken together, Caco-2 cells stable transfected with PXR show increased levels of P-gp 
expression. However, functional induction of PXR-target genes by rifampicin is not as explicit as 
in LS180 cells and further evaluations are needed to establish a definite PXR-inducible Caco-2 
cell system. 
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5 Curcuma longa 
 
5.1 Effects of Curcuma-Extracts and Curcuminoids on Expression of 
Intestinal ABC-Transporters and Cytochrome P450 
 
5.1.1 Abstract 
Background and Purpose: Curcuma longa L. is a widely used spice. Its main ingredients, the 
curcuminoids, are used in the treatment of inflammatory diseases and cancer. Bioavailability of 
curcuminoids is low and huge amounts remain in the intestine. We therefore aimed to investigate 
the interaction potential with ATP-binding cassette transporters (ABC-transporters) and 
cytochromes P450 (CYPs) in an intestinal cell line (LS180). Intestinal ABC-transporters and 
CYP enzymes play a major role in drug absorption and consequently changes in their expression 
level could lead to interactions. 
Experimental Approach: The intestinal LS180 cell line was incubated with different curcuma 
extracts, the single curcuminoids, curcumin, demethoxycurcumin and bisdemethoxycurcumin, 
and a curcuminoid mixture. Changes in mRNA expression of the ABC-transporters MDR1 and 
BCRP and the cytochromes CYP3A4 and 1A2 were measured by real-time RT-PCR. 
Key Results: MDR1 mRNA expression was significantly but not relevant downregulated by the 
curcuminoids, whereas the extract had no significant effect. BCRP expression in our cell system 
was very low and therefore, we could not quantify any effects on BCRP mRNA expression. 
CYP3A4 and 1A2 mRNA expression did not alter significantly after treatment. 
Conclusions and Implications: Curcuma extracts, the single curcuminoids and a curcuminoid-
mixture have no relevant effect on the investigated ABC-transporters and CYPs mRNA 
expression in our cell system. Further studies are required to evaluate its effects in vivo. 
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5.1.2 Introduction 
Curcuma longa L. (turmeric) belongs to the family of zingiberaceae. Its rhizome is widely used as 
spice and food-coloring agent. It also has a long history in traditional Indian medicine. The 
mainly investigated constituents of turmeric are the three curcuminoids curcumin, 
demethoxycurcumin and bisdemethoxycurcumin. They are supposed to be responsible for the 
biological activities of turmeric such as anti-inflammatory or antioxidant activities. Several in vitro 
studies showed that curcumin interacts with a variety of proteins such as transcriptional factors, 
inflammatory cytokines, enzymes, kinases, growth factors, receptors etc. Curcumin also regulates 
expression of different anti-inflammatory agents and studies with curcumin suggest that it has an 
antiproliferative potential. Clinical trials with curcumin were performed mainly in the field of 
anti-inflammatory or anti-cancer therapy (Goel et al., 2008). 
Unfortunately, curcumin has a low oral bioavailability mainly due to poor enteral absorption and 
rapid metabolism. Studies in rats and humans showed low plasma concentrations after oral 
application. Higher systemic concentrations were achieved after inhibition of glucuronidation 
(Shoba et al., 1998). Studies in rats revealed that after oral intake most of the applied drug 
remains in the intestinal tract (Ravindranath and Chandrasekhara, 1980). 
The intestine forms the first barrier for drugs or other xenobiotics. Physicochemical properties of 
the drug itself and active efflux-transport or metabolism mainly form this barrier. Among these 
efflux-transporters P-glycoprotein (P-gp, MDR1) is the most prominent. It belongs to the class of 
ATP-binding-cassette transporters (ABC-transporters) and has broad substrate specificity for 
different compounds such as anticancer drugs, antibiotics, antivirals or immunosuppressive 
agents. P-gp is regulated via the human pregnane X receptor (hPXR) (Geick et al., 2001) Breast 
cancer resistance protein (BCRP) is another ABC-transporter with an important role in the 
intestine. BCRP is a half-transporter and is also highly expressed in the intestine. Its substrate 
specificity is partly overlapping with P-gp. The regulation of BCRP is yet not fully understood, 
but there is some evidence that upregulation of BCRP is mediated via the aryl hydrocarbon 
receptor (AhR) (Ebert et al., 2005). 
Important metabolising enzymes in the intestine are the cytochromes P450 (CYP). They belong 
to the haemoproteins and metabolise lipophilic substrates of diverse structures. CYPs are 
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important in oxidative, peroxidative and reductive metabolism of several endogenous compounds 
and xenobiotics. CYP3A4 plays a major role in intestinal metabolism of various drugs. It has a 
broad substrate specificity that overlaps with P-gp substrates to a large extent. This combination 
leads to an effective barrier for various drugs (Doherty and Charman, 2002). In parallel with P-
gp, CYP3A4 also is regulated via hPXR (Bertilsson et al., 1998). CYP1A2 metabolises 
preferentially arylamines and N-heterocyclics and its expression is regulated via AhR (Nebert and 
Russell, 2002). 
Interactions with ABC-transporters or CYPs can lead to drug-drug interactions. Functional 
inhibition of ABC-transporters or CYPs by curcumin has been shown (Appiah-Opong et al., 
2007), (Chearwae et al., 2004). It was further shown that the curcuminoids reduce MDR1 
mRNA expression (Limtrakul et al., 2004) and that curcumin increases BCRP mRNA (Ebert et 
al., 2007).  
In this study we investigated the effects of different curcuma extracts and the single curcuminoids 
on the expression of MDR1, BCRP and CYPs in an intestinal cell culture model. Additionally, 
effects on gene expression by the curcuminoid content in the extract were compared to the full 
extract and to pure curcuminoids.  
 
5.1.3 Methods 
Materials 
Rifampicin and benzpyrene (Sigma Aldrich, Buchs, CH) were dissolved in dimethylsulfoxide 
(DMSO). Curcumin, demethoxycurcumin and bisdemethoxycurcumin were purchased from 
Chromadex (Irvine, CA, USA) and dissolved in ethanol. Curcuma sigma (Sigma-Aldrich) 
(contains about 70% curcumin and 30% demethoxy- and bisdemethoxycurcumin) was dissolved 
in ethanol. The different curcuma extract were received from Vitaplant AG (Witterswil, CH) and 
were dissolved in their individual extracting agent. 
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Cell Culture 
LS180 cells were purchased from American Type Culture Collection (Manassas, NE, USA). They 
were cultured in Dulbecco’s modified Eagle’s medium with Glutamax-I, supplemented with 10% 
fetal bovine serum, 1% non-essential amino acids, 1% sodium pyruvate and 50 µg/ml 
gentamycin (Invitrogen AG, Basel, Switzerland). Culture conditions were 37°C with humidified 
air and 5% CO2. Cells were seeded in 12 well-dishes (3.8 cm2 per well, BD Falcon AG, Allschwil, 
Switzerland) 3 days before starting the incubation with curcuma-extracts curcuminoid mixture 
and the single curcuminoids. Incubation was performed during 72 hours with medium change 
every 24 hours. Toxicity was tested in advance using sulforhodamine B staining (Skehan et al., 
1990). All curcuma-extracts, curcuma sigma and the single curcuminoids were used in a 
concentration of 10 µg/ml. Rifampicin was used at 10 µM. 
 
Real time RT-PCR: see chapter 2.2 
Sequences for primer and probes are listed in Table 1 
 
5.1.4 Results 
Curcuma Extracts 
Curcuma extracts were produced and analysed by Vitaplant AG (Witterswil, CH). Extracting 
agents were composed of different concentration of ethanol:water. In Table 6 analysis on 
curcuminoids content is listed. Curcuma mixture was made by mixing single curcuminoids in the 
concentration of Curcuma 70 extract. 
  
Effects of Curcuma-Extracts and Curcuminoids on ABC-Transporters and CYPs Expression 
111 
Table 6 Composition of curcuma extracts 
 Extracting agent Curcuminoids
Total 
Curcumin Demethoxy-
curcumin 
Bisdemethoxy-
curcumin 
Curcuma 30 30% Ethanol 1.07% 0.52% 0.28% 0.27% 
Curcuma 50 50% Ethanol 16.93% 8.12% 4.57% 4.24% 
Curcuma 70 70% Ethanol 25.85% 15.61% 5.97% 4.27% 
Curcuma 90 90% Ethanol 27.77% 16.65% 6.62% 4.50% 
Curcuma 100 100% Ethanol 37.52% 22.39% 9.00% 6.13% 
 
MDR1 and BCRP mRNA Expression 
The effect of the different curcuma extracts and the single curcuminoids on MDR1 mRNA 
expression was investigated. LS180 were incubated with the different extracts and the single 
curcuminoids, rifampicin served as positive control for MDR1 induction. mRNA expression was 
analysed using real time RT-PCR. In Figure 31 we observed a strong induction of MDR1 by the 
positive control. No significant effect on MDR1 mRNA expression was observed in cells treated 
with the different extracts (Figure 31A). Curcumin, bisdemethoxycurcumin and the curcuma 70 
mix (curcuminoid-mixture) showed a small but statistically significant downregulation of MDR1 
mRNA expression (Figure 31B). BCRP is unfortunately only at very low levels expressed in 
LS180 cells; therefore, quantification was not possible. 
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Figure 31 MDR1 mRNA expression in LS180 cells after 72 hours incubation with different curcuma extracts (A) 
and single curcuminoids (B). Rifampicin 10 µM served as positive control for induction. Data represent mean±s.e.m. 
(n=3). *p<0.05, ***p<0.001 vs. control 
 
CYP3A4 and CYP1A2 mRNA Expression 
The mRNA expression of intestinal CYP3A4 after treatment with curcuma extracts was 
investigated. We could see no significant effect on intestinal CYP3A4 expression after treatment 
with curcuma extracts. Rifampicin served as positive control and showed a strong induction 
(Figure 32). mRNA expression of CYP1A2 after treatment with the extracts or the curcuminoids 
did not alter significantly (data not shown). 
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Figure 32 CYP3A4 mRNA expression in LS180 cells after 72 hours incubation with different curcuma extracts (A) 
and single curcuminoids (B). Rifampicin 10 µM served as positive control for induction. Data represent mean±s.e.m. 
(n=3). ***p<0.001 vs control. 
 
5.1.5 Discussion 
Extracts of curcuma longa L. are a widely used spice. Data with curcumin have been shown that 
it is hardly absorbed after oral administration and a large amount remains in the intestine 
(Ravindranath and Chandrasekhara, 1980). Regarding drug-drug interactions in the intestine, it 
is relevant to investigate whether curcumin has effects on ABC-transporters or CYPs expression. 
An induction of ABC-transporters and CYPs could decrease bioavailability of their substrates and 
on the other hand, a downregulation could increase their bioavailability or could impair the 
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natural barrier function of the intestine. Therefore, we investigated the effect of different curcuma 
extracts and the single curcuminoids on P-gp, BCRP and CYPs mRNA expression in the 
intestinal cell model LS180. Our data showed that neither the extracts nor the single 
curcuminoids had a relevant effect on ABC-transporters and CYPs mRNA expression.  
Curcuma extracts containing different determined amounts of curcuminoids did not show the 
same effect on MDR1 mRNA expression compared to the single curcuminoids. Extracts had no 
significant effect while the single curcuminoids significantly downregulated MDR1 mRNA 
expression. This slightly differing result could be due to the concentrations of curcuminoids 
which are much smaller in the extract than in the single curcuminoids. Therefore, we mimicked 
one extract by composing a curcuminoid-mixture with the same concentration of curcumin, 
demethoxycurcumin and bisdemethoxycurcumin as it exists in the extract. Interestingly, the 
curcuminoid-mixture showed the same small downregulation of MDR1 mRNA expression as the 
single curcuminoids while the extract showed no alteration. Similar effects were observed in 
Caco-2 cells by Hou et al. Incubation with curcuma extracts induced MDR1 expression while 
curcumin showed a slight downregulation (Hou et al., 2008). Further components of curcuma-
extracts that are not yet evaluated possibly have also effects on regulation of MDR1 mRNA 
expression. Other studies with the single curcuminoids showed a downregulation of MDR1 
mRNA and protein level with the most powerful effect using bisdemethoxycurcumin (Limtrakul 
et al., 2004). On functional level, they concluded that curcumin is the most potent inhibitor of 
P-gp activity (Chearwae et al., 2004).  
Results on CYP3A4 mRNA expression revealed a similar pattern like MDR1, but in contrast to 
MDR1, no significant effects were achieved. Effects of the single curcuminoids on CYP3A4 
mRNA expression are not yet described in literature. Hou et al. investigated different curcuma 
extracts and curcumin in Caco-2 cells and revealed that CYP3A4 activity and protein expression 
was reduced after 72 hours incubation. In contrast to this finding, they could not see a reduction 
in CYP3A4 mRNA expression, concluding that the effect on protein level might be due to 
reduced protein stability (Hou et al., 2007). Another study in the intestinal cell culture model 
Caco-2 showed that curcumin efficiently inhibited P-gp and CYP3A4 activity (Zhang and Lim, 
2008). In vivo data in Sprague-Dawley rats revealed that curcumin downregulated intestinal P-gp 
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and CYP3A4 protein and consequently substrates of P-gp and CYP3A4 reached lower AUC 
(Zhang et al., 2007). 
Taken these results together, changes in mRNA expression of MDR1 and CYPs after incubation 
with curcuma extracts and single curcuminoids are only small in our intestinal cell culture model. 
Interactions of curcuminoids and curcuma-extracts with P-gp and CYPs on mRNA expression 
level are described but further studies are indicated to identify its relevance in vivo. 
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5.2 Anti-inflammatory Effects of Curcuminoids and a Curcuma-extract in 
Intestinal Cells 
 
5.2.1 Abstract 
Background and Purpose: Curcuma was used in traditional Asian medicine as agent against 
inflammation. Several scientific data also indicate anti-inflammatory effects of the curcuminoids 
which are the main biological active components. Chronic inflammatory diseases of the intestine 
could be an indication for treatment with curcuminoids. We therefore investigated anti-
inflammatory effects of a curcuma extract, the single curcuminoids curcumin, 
demethoxycurcumin and bisdemethoxycurcumin, and a curcuminoid mixture in an intestinal cell 
culture model. 
Experimental Approach: LS180 cells were stimulated with TNF-α (tumor necrosis factor) in 
order to induce inflammatory conditions. Cells were concomitantly treated with a curcuma 
extract, curcuminoids and a curcuminoid mixture and effects on TNF-α, Il-8 (interleukin-8), 
iNOS (intrinsic nitric oxide synthase), 5-LOX (5-lipoxygenase), and COX-2 (cyclooxygenase-2) 
mRNA expression was measured by real-time RT-PCR. Direct inhibitory effects of the curcuma 
extract on COX-2 activity were measured by detecting synthesis of prostaglandin E2 (PGE2).  
Key Results: Stimulation with TNF-α revealed an induction of all investigated pro-inflammatory 
proteins except for 5-LOX. This induction was significantly abolished for iNOS or COX-2 
mRNA expression after treatment with the curcuminoids or curcumin, respectively. In stimulated 
cells, Il-8 mRNA expression was not altered after treatment with the curcuminoids and the 
extract. TNF-α mRNA expression did not vary significantly after treatment with the 
curcuminoids but treatments tended to downregulate the auto-induction by TNF-α. 5-LOX 
mRNA expression was downregulated after stimulation with TNF-α and treatment with 
curcuminoids. Additionally to mRNA expression, COX-2 activity was directly inhibited by the 
curcuma extract. 
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Conclusions and Implications: Anti-inflammatory effects of curcuminoids were shown by a 
decrease in mRNA expression of different inflammatory proteins. Direct inhibition of COX-2 by 
the curcuma extract could be demonstrated. Further studies on protein level and in vivo should 
be performed to verify the anti-inflammatory effects and to gain insight into the possible 
therapeutic mechanisms. 
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5.2.2 Introduction 
Powdered rhizome of Curcuma longa L., turmeric, is widely used in the food industry as spice or 
coloring agent. Curcuma longa L. grows primarily in southern Asia and therefore it is also used in 
traditional Chinese and Indian medicine. Turmeric has been used in traditional Asian medicine 
for treatment of inflammation (Ammon and Wahl, 1991). For many traditional medicines, there 
is sparse scientific information about its efficacy and security. Recent studies gave attention to 
curcuma extracts and curcuminoids, which are suggested to be responsible for the biological 
activity of turmeric. In vitro studies have shown that curcumin interacts with several molecular 
targets such as transcriptional factors (e.g. nuclear-factor-kappa-B (NFκB)), inflammatory 
cytokines, enzymes (e.g. cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX)). Preclinical studies 
with curcumin indicate that it has a chemopreventive potential in cancer. Clinical studies in 
humans show evidence that curcumin is safe and well tolerated. It exerts chemopreventive effects 
against multiple human cancers and has antioxidant, anti-inflammatory and anti-rheumatic 
properties (Goel et al., 2008) (Aggarwal et al., 2008) (Aggarwal and Sung, 2009). 
Inflammation is a process that involves many complex pathways. One of those pathways is 
associated with a large number of mediators, which initiate inflammatory response and which 
recruit and activate other cells to the site of inflammation. Some cytokines, including TNF-α, IL-
1, IL-8, IL-12, IFN-γ among others, belong to those mediators. They are regulatory polypeptides 
and are produced after appropriate stimuli e.g. lipopolysaccharide (LPS) from gram negative 
bacteria. TNF-α and IL-1β are two cytokines that are involved in the initiation of inflammation 
These proteins exhibit inductory effects on other cytokines and are able to activate the 
arachidonic acid pathway. Key-enzymes of the arachidonic acid pathway are cyclooxygenase 
(COX), which produce prostaglandins (PG) and thromboxanes, and 5-lipoxygenase (5-LOX), 
which produce leuktrienes (LT). Metabolites of this pathway also participate in the inflammatory 
process. Effects of prostaglandins are local vasodilatation and sensitising of nociceptors, while 
leukotrienes lead to an increase in permeability of blood vessels. Several transcription factors such 
as NF-κB and AP-1 are known to be part of the production of cytokines and arachidonic acid 
metabolising enzyme COX-2. 
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Curcumin has been shown to have effects on several of these pro-inflammatory components. In 
vitro studies revealed that curcumin reduces TNF-α and IL-1β production and inhibits NF-κB 
activation (Chan, 1995). Curcumin has also been reported to reduce expression of inducible 
nitric oxide synthase (iNOS), an inflammation-induced enzyme that catalyses the production of 
nitric oxide (NO) (Chan et al., 1998). Other in vitro experiments showed that curcumin reduces 
COX-2 expression and inhibits the catalytic activities of 5-LOX (Lantz et al., 2005), (Hong et al., 
2004). Hidaka et al reported that curcumin could inhibit the production of IL-8, which is a 
chemotactic cytokine and is able to direct leukocyte migration, activate inflammatory responses 
and help tumour growth (Hidaka et al., 2002). 
Bioavailability of curcuminoids is very low; therefore the investigation of local effects of 
curcuminoids in the intestine is of interest. Ulcerative colitis and Crohn’s disease are chronic 
inflammatory diseases of the intestine. Protective effects after curcumin treatment were observed 
in mouse models of ulcerative colitis (Salh et al., 2003), (Ukil et al., 2003).  
In this study, we investigated effects of the 3 main curcuminoids, curcumin, demethoxycurcumin 
and bisdemethoxycurcumin, a curcuma extract and a curcuminoid-mixture on defined pro-
inflammatory mediators in a human intestinal cell model. 
 
5.2.3 Methods 
Materials 
Curcumin, demethoxycurcumin and bisdemethoxycurcumin were purchased from Chromadex 
(Irvine, CA, USA) and dissolved in ethanol. Curcuma 70 extract was produced by Vitaplant AG 
(Witterswil, CH) and dissolved in its extracting agent (see chapter 5.1.4) Curcuminoid mixture 
was made by mixing pure curcuminoids in the concentration of the extract (see Table 6). TNF-α 
was obtained from PeproTech EC Ltd (London, UK). 
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Cell Culture 
The LS180 cell line was purchased from American Type Culture Collection (Manassas, NE, 
USA). LS180 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 
Glutamax-I, supplemented  with 10% fetal bovine serum (FBS), 1% non-essential amino acids, 
1% sodium pyruvate, 50 µg/mol gentamycin (Invitrogen AG, Basel, Switzerland). Cells were 
seeded into 12-well plastic culture dishes (BD Falcon AG, Allschwil, Switzerland) and were 
maintained in a humified 37°C incubator with 5% carbon dioxide in air atmosphere. One day 
before starting incubation with curcuminoids, cells were starved in DMEM containing only 
0.25% FBS. The first day of incubation, cells were stimulated with TNF-α (100 ng/ml) in 
DMEM containing 0.25% FBS. The treatment with curcuminoids, the curcuma 70 extract and 
the curcuma extract mixture was added to the culture medium concomitantly with the stimulus 
(TNF-α). After 24 hours, the incubation was continued for another 48 hours without stimulus. 
In this case, medium and treatment was changed every 24 hours. 
 
Real-time RT-PCR: see chapter 2.2 
Sequences for primers and probes are listed in Table 1. 
 
COX-2 Assay 
Activity of COX-2 enzyme was measured using the prostaglandine E2 –EIA (enzyme immune 
assay)-kit (Cayman Chemical, Michigan, USA). Curcuma 70 extract was incubated in different 
concentration for 15 minutes with the assay mixture (0.1 M Tris-HCl, 2 mM Phenol, 5 mM 
EDTA and Hematin) and COX-2 enzyme. As negative control, a heated sample was used where 
the enzyme was inactivated. Indomethacin was used as positive control of COX-2 inhibition. To 
start the reaction, arachidonic acid is added and the mixture is incubated for 3 minutes at room 
temperature. During this time production of PGE2 takes place. The reaction was stopped by 
adding acetic acid (1 N) and neutralising with NaOH (1 N) afterwards. The inhibition of COX-
2 enzyme is determined by measuring quantitatively PGE2 with ELISA. PGE2 bound with 
acetylcholine-esterase (AChE) competes with the PGE2 produced by COX-2 for binding at the 
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PGE2 specific antibody for 24 hours. Afterwards acetylcholine-containing Ellman’s reagent was 
added for 2 hours and absorbance was measured at 415 nm. 
 
5.2.4 Results 
mRNA Expression of Inflammatory Proteins 
LS180 cells were stimulated with TNF-α to induce inflammation and treated with the 3 
curcuminoids curcumin, demethoxycurcumin and bisdemethoxycurcumin, a curcuma extract and 
a curcuminoid-mixture, which mimics the curcuminoid content of the curcuma extract. mRNA 
expression of TNF-α, IL-8, iNOS, COX-2 and 5-LOX after 72 hours treatment was analysed 
using real-time RT-PCR. After the stimulus with TNF-α an induction of mRNA expression of all 
investigated genes was reached except for 5-LOX, where a downregulation was measured.  
TNF-α mRNA expression was induced after stimulation with TNF-α (auto-induction). 
Treatment with the curcuminoids demethoxycurcumin and bisdemethoxycurcumin reduced this 
auto-induction about 50% but did not reach significance. Incubation with curcumin showed 
variable effects in our assays and the relation between stimulated and curcumin treated cells in 
TNF-α expression level can therefore not be well interpreted. Treatment with the extract or the 
curcuminoid-mixture did not significantly reduce the auto-induction of TNF-α (Figure 33A).  
After treatment with the curcuminoids or the extract, IL-8 mRNA expression did not change 
significantly compared to the stimulation without treatment. Nearly all treatments investigated 
lead to a significant induced IL-8 mRNA expression compared to control (Figure 33B).  
iNOS mRNA expression was significantly induced after stimulation with TNF-α, but after 
treatment with the curcuminoids this induction was significantly reduced and reached the level of 
not-stimulated cells (Figure 33C).  
5-LOX mRNA expression was not induced after stimulation with TNF-α, it was even 
significantly downregulated compared to control. Additional treatment with the curcuminoids or 
the extract did not change 5-LOX mRNA expression compared to the stimulated cells, all were 
significantly downregulated compared to control (Figure 33D).  
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COX-2 mRNA expression was significantly induced in the TNF-α stimulated cells. Additional 
treatment with curcuminoids could again neutralise this induction down to the level of not-
stimulated cells, but significance was only reached with curcumin (Figure 33E). 
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Figure 33 mRNA expression of TNF-α (A), IL-8 (B), iNOS (C), 5-LOX (D) and COX-2 (E) after stimulation with 
TNF-α and treatment with the indicated substances for 72 hours. Data represent mean ± s.e.m (n=3-6 except Figure 
1A: DMC n=2). # p<0.05 ## p<0.01 ### p<0.001 compared to control, * p<0.05 **p<0.01 compared to stimulation 
with TNF-α. 
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COX-2 Inhibition Assay 
Using the PGE2-EIA kit, we measured COX-2 inhibition after addition of different 
concentration of curcuma 70 extract. COX-2 is responsible for the conversion of arachidonic acid 
into prostaglandins. A competitive enzyme immunoassay quantitatively gives information about 
the produced PGE2 and is therefore indicative for the inhibition of COX-2.  
Indomethacin, an established COX-2 inhibitor, was used as positive control. The concentration 
of indomethacin where 50% of total enzyme activity was inhibited (IC50-value) was 3 µM (1, 07 
µg/ml). Curcuma 70 extract was measured in different concentrations and its IC50 was calculated 
at 45 µg/ml. (Figure 34) 
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Figure 34 Percentage of COX-2 activity after addition of different concentrations indomethacin (A) and curcuma 70 
extract (B). Data of curcuma 70 extract represent mean ± s.e.m (n=3) 
 
5.2.5 Discussion 
Powdered rhizome of Curcuma longa L., turmeric, is used in traditional Indian medicine to treat 
inflammations, wounds and tumours (Ammon and Wahl, 1991). Curcuminoids such as 
curcumin, demethoxycurcumin and bisdemethoxycurcumin are suggested to be responsible for its 
biological activities. Curcumin is the best characterised curcuminoid and showed several anti-
inflammatory actions in vitro. Mechanistic insights into its anti-inflammatory action revealed 
interactions with the transcriptional factor NFκB and mitogen-activated-protein-kinases 
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(MAPK), which are responsible for transcription of several inflammatory mediators (Cho et al., 
2007).  
We investigated anti-inflammatory effects of curcuminoids, a curcuma extract and a 
curcuminoid-mixture on mRNA expression of TNF-α, IL-8, iNOS, COX-2 and 5-LOX in the 
intestinal cell culture model LS180.  
TNF-α is one of the inflammatory proteins which is responsible for initiation of inflammation 
and activation of arachidonic acid metabolism. Stimulation of cells with TNF-α led to an increase 
in TNF-α mRNA expression, which represents initiation of inflammation. Reduction of this 
induction suggests anti-inflammatory effects. The curcuminoids, the curcuma extract and the 
curcuminoid-mixture showed a tendency to reduce TNF-α mRNA expression but did not reach 
significance. Curcumin unfortunately did not show a consistent pattern in our experiments and 
its effects on TNF-α mRNA expression in LS180 cells has to be evaluated in further experiments. 
Nevertheless, it was shown in literature that curcumin could decrease TNF-α production and 
further inhibit nuclear translocation of NFκB (Chan, 1995), (Abe et al., 1999). However, it has 
to be taken into account, that these data from literature measured TNF-α protein production 
from monocytes and functional activity of TNF-α while our data analysed the mRNA expression 
of TNF-α in an intestinal epithelial cell line.  
IL-8, a cytokine which is produced by epithelial cells and induces chemotaxis, was also 
investigated in our cell system. Stimulation of TNF-α induced IL-8 mRNA expression but the 
curcuminoids and the extract could not reverse this effect. This finding is in accordance with the 
results of Cho et al. who could not detect an inhibitory effect on IL-8 production with curcumin 
treatment in TNF-α-stimulated keratinocytes (Cho et al., 2007). However, the results seem to be 
contradictory to Kim et al. who investigated the effect of curcumin on IL-8 mRNA and protein 
expression in human umbilical vein endothelial cells (HUVECs). In contrast, they observed a 
downregulation on TNF-α -induced IL-8 mRNA expression after curcumin treatment (Kim et 
al., 2007). The differences observed in these studies might be explained by the unequal cell 
system.  
iNOS plays an important role in inflammation and tumour genesis through production of the 
free radical nitric oxide (NO). iNOS mRNA expression was induced after TNF-α stimulation 
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and additional treatment with the curcuminoids, the curcuma-extract and the curcuminoid-
mixture could neutralise this induction. These data are in agreement with the results of Pan et al., 
who demonstrated that curcumin inhibits NFκB activation which is essential for iNOS induction 
(Pan et al., 2000). 
Unexpected results were observed at 5-LOX mRNA expression after stimulation with TNF-α. 5-
LOX mRNA expression was significantly reduced after stimulation with TNF-α and curcuminoid 
treatment did not further change 5-LOX mRNA expression. In literature it was shown that 
addition of TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF) to HL-60 
cells could induce 5-LOX activity (Steinhilber et al., 1993). For GM-CSF a significant 
augmentation of 5-LOX mRNA expression was observed 18 hours after incubation in human 
neutrophils (Stankova et al., 1995). These data show increased 5-LOX activity by stimulation 
with TNF-α and GM-CSF. Additionally, after stimulation with GM-CSF increased 5-LOX 
mRNA expression was shown. We measured 5-LOX mRNA expression after stimulation with 
TNF-α which is not described by Stankova et al. and Steinhilber et al. Nevertheless, it is unclear, 
why we observed a downregulation in our cell system. A possible explanation why we cannot see 
an induction of 5-LOX mRNA expression after TNF-α -stimulation could be the short half-life 
of this protein. It was shown that half-life of 5-LOX in HL-60 is approximately 26 hours 
(Kargman and Rouzer, 1989). However, the downregulation of 5-LOX after stimulation remains 
to be elucidated. 
COX-2, another enzyme of the arachidonic acid pathway, was clearly upregulated after TNF-α -
stimulation and curcumin could significantly neutralise this induction. In addition to this 
transcriptional data, direct inhibitory effects on COX-2 activity showed that curcuma 70 extract 
could inhibit PGE2 production. It is reported that curcumin reduces mRNA and protein 
expression of COX-2 in an intestinal cell model. Following incubation with curcumin a reduced 
PGE2 production was measured (Goel et al., 2001), (Zhang et al., 1999). Lantz et al. investigated 
a dichloremethane-methanol (1:1) extract of Curcuma longa L. and analysed its fractions on 
inhibition of PGE2 and TNF-α production in HL-60 cells. The fraction containing the 
curcuminoids provoked after 24 hours incubation an IC50 value of PGE2 production of 0.9 
µg/ml, whereas the fractions containing the turmeric oils reached an IC50 of 0.084 µg/ml. 
Interestingly, curcumin induced a downregulation of COX-2 mRNA expression while turmeric 
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oils did not (Lantz et al., 2005). These data indicate that besides COX-2 mRNA downregulation, 
components of the extract probably interact with COX-2 enzyme on another level. Our data 
show, that the curcuma-extract directly inhibits COX-2 activity. However, the IC50 value of 
PGE2 production was 45 µg/ml for the curcuma extract and is higher compared to indomethacin 
which achieved an IC50 value of 3 µM (1.07 µg/ml). Further inhibition experiments with the 
single curcuminoids on COX-2 activity are indicated. Analysing the effect of the curcuminoid-
mixture, which mimics the curcuminoid content of the extract, on COX-2 activity would give 
information about the role of curcuminoids in direct COX-2 inhibition.  
In conclusion, after stimulation with TNF-α, the curcuminoids could effectively downregulate 
different cytokines or enzymes taking part in the inflammatory response. The effects of the 
curcuma-extract were mostly weaker compared to the single curcuminoids. While the extract 
could directly inhibit COX-2 activity, inhibition by the single curcuminoids has to be analysed in 
further experiments. The effects found in our in vitro system have to be verified in an in vivo 
system to gain further insights into its therapeutic effects in inflammation. 
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6 Conclusion and Outlook 
 
Drug absorption in the intestine is a fundamental requirement for oral drug therapy. Transport 
proteins and metabolising enzymes are important determinants of drug bioavailability. Decreased 
absorption of orally administered drugs due to efflux transport proteins is a well known 
phenomenon. P-gp and BCRP seem to play an important role since they exhibit high intestinal 
expression levels and are involved in the efflux transport of many drugs.  
In this thesis, the impact of the drug transporters P-gp and BCRP on drug absorption was 
investigated. We established an intestinal in vitro model with selective and concomitant knock-
down of P-gp and BCRP. Using this model, we were able to examine substrates of both, P-gp and 
BCRP, and to evaluate the impact of each transporter on absorption of these substrates. The 
tyrosine kinase inhibitor imatinib and the anti-retroviral drug abacavir were described as 
substrates of P-gp and BCRP. The evaluation of drug absorption in our cell system revealed that 
in the case of these two substrates probably P-gp plays a more important role than BCRP and 
possibly can compensate drug efflux transport when BCRP is inhibited. However, these results 
have to be evaluated in further experiments to rule out other interferences which possibly could 
affect our system. 
Beside this inhibition of P-gp or BCRP, induction of these transporters might negatively 
influence drug absorption. Lower systemic available drug concentration due to higher export 
transport could be the consequence. Efflux transport was described as a cause for therapy 
resistance in several diseases such as cancer. Increased P-gp expression in steroid treated IBD-
patients was also described and it is discussed whether this could be a possible cause of therapy 
resistance. 
Budesonide, a frequently used glucocorticoid, regulated P-gp expression differently in two 
common intestinal cell lines LS180 and Caco-2. Induction of P-gp expression was observed in 
LS180 cells where the nuclear receptor PXR is functional active. Collaborative work revealed that 
budesonide is a ligand of PXR and has the potential to induce PXR target genes such as P-gp and 
CYP3A4 via this pathway. In vivo data in mice, however, showed only modest gene induction, 
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which mainly occurred in the intestine. These data indicate that budesonide has the potential to 
induce PXR-target genes in the intestine, but only to a slight extent. Therefore, risk for drug-
interactions due to budesonide seems to be low but cannot be ruled out completely. 
The well established intestinal cell line Caco-2 exhibits properties of small intestinal epithelium 
but lacks functional PXR expression. Therefore, we stably transfected PXR into Caco-2 cells. In 
our cell system, P-gp expression was constitutively increased and could be induced by the PXR 
ligand rifampicin. Since induction effects were not as pronounced as in LS180 cells, further 
evaluations are needed. However, after further evaluation, this system could serve as an in vitro 
intestinal cell culture model with combined properties for intestinal transport and induction 
studies. 
Curcuma longa L. is a widely used spice and the curcuminoids, which account for its main 
constituents, are being investigated for treatment of cancer, inflammation and other diseases. The 
curcuma extracts and the curcuminoids did not change the expression of P-gp and CYP to a 
major extent. Thus, a curcuma-mediated risk for drug-interactions due to transcriptional 
regulation of ABC-transporters and CYPs seems to be low but has to be further evaluated in vivo. 
A downregulation of several TNF-α induced pro-inflammatory proteins after treatment with 
curcuminoids or curcuma extract suggest anti-inflammatory effects in the intestinal cell line 
LS180. Further investigations on anti-inflammatory effects in the intestine have to be performed 
in vivo. The efficacy of the curcuminoids or the curcuma extract in treatment of inflammatory 
diseases in the intestine remains to be elucidated. 
In this thesis we provided data on transcriptional regulation and impact of ABC-transporters in 
intestinal cell lines. Newly generated Caco-2 clones with a specific knock-down of P-gp or BCRP 
mRNA expression were used to get knowledge of the impact of each transporter on transport of 
two different drugs. Topical effective anti-inflammatory drugs such as budesonide and 
curcuminoids were analysed on transcriptional level to investigate the interaction potential of 
ABC-transporters and CYPs. PXR was stably transfected into Caco-2 cells in order to have a tool 
for transcriptional interaction studies of P-gp and CYPs. However, our cell systems need further 
evaluations, nevertheless as a future perspective, screening of new drugs on transcriptional 
regulation and evaluations of the impact of P-gp- and BCRP-transport could be performed. 
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